


Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care: A Workshop

Co-Hosts

American Society of Clinical Oncology
National Cancer Policy Forum



The Keck Center – Room 100
500 Fifth Street, N.W.
Washington, DC 20001

Live Webcast:

[Assessing and Advancing Progress in the Delivery of High-Quality Cancer
Care: A Workshop | National Academies](#)

October 5, 2023

Dear Colleagues,

Thank you for joining us for *Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care: A Workshop*. The American Society of Clinical Oncology and the National Cancer Policy Forum—a convening body of the National Academies of Sciences, Engineering, and Medicine—are co-hosting this workshop to examine progress in the delivery of high-quality cancer care since the Institute of Medicine’s 2013 consensus report, [*Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis*](#).

This workshop will provide an opportunity for the cancer community to gauge progress on implementation of the report recommendations and to discuss persistent challenges in achieving excellent and equitable cancer care. Workshop sessions include an overview of the report and how the landscape of oncology care has changed in the past decade, patient perspectives and lived experiences with the quality of cancer care, opportunities to promote patient-centered cancer care delivery, the workforce caring for patients living with and beyond cancer, cancer care delivery and payment models, and evidence generation to improve the quality of cancer care. Workshop participants will highlight potential policy, practice, and research actions to ensure high-quality cancer care for all people.

We welcome your involvement in the workshop. Please use the microphones in the room or the chat box on our [website](#) to ask questions, and please mention your name and affiliation. The proceedings of the workshop will be published by the National Academies Press and may incorporate your comments and ideas. Archived presentations and videos from the workshop will also be available on the website.

We look forward to this important workshop.

Sincerely,


Patricia A. Ganz, M.D. (Chair)

Distinguished Professor
Health Policy & Management and Medicine
UCLA Fielding School of Public Health
David Geffen School of Medicine at UCLA
Director, Cancer Prevention & Control Research
Jonsson Comprehensive Cancer Center

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care: A Workshop October 5-6, 2023

Workshop Co-Hosts
National Cancer Policy Forum
American Society of Clinical Oncology

[Workshop Website](#)
Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001



WORKSHOP AGENDA

Thursday, October 5, 2023 Eastern Time Zone	
8:30 am	Breakfast and Registration
9:00 am	Welcome from NCPF and ASCO Leadership Rob Winn, National Cancer Policy Forum and Virginia Commonwealth University Julie Gralow, American Society of Clinical Oncology
9:15 am	Session 1: Workshop Overview <i>Co-Moderators</i> Patricia Ganz, University of California, Los Angeles Laura Levit, American Society of Clinical Oncology Overview of the Report Recommendations and Implementation Progress (15 minutes) Patricia Ganz, University of California, Los Angeles What Changes in the Landscape of Oncology Care Have Occurred Since the Report was Released? (15 minutes) Robin Zon, President Elect, American Society of Clinical Oncology Panel Discussion (45 minutes) Include speakers and panelists: <ul style="list-style-type: none"> • Shelley Fuld Nasso, National Coalition of Cancer Survivorship • Lori Pierce, University of Michigan • Fumiko Chino, Memorial Sloan Kettering Cancer Center • Heidi Klepin, Wake Forest University
10:30 am	Break
10:45 am	Patient Voices and Lived Experiences <i>Moderator:</i> Ishwaria Subbiah, Sarah Cannon Research Institute <ul style="list-style-type: none"> • Beverly Canin, Cancer and Aging Research Group • Sarah Greene, Independent Consultant • Patty Spears, Lineberger Comprehensive Care Center; University of North Carolina Chapel Hill

11:05 am	<p>Session 2: From Standard of Care to Clinical Trials: Advancing the Continuum of Patient-Centered Cancer Care <i>Co-Moderators</i> Ishwaria Subbiah, Sarah Cannon Research Institute Laurel Pracht, West Valley Ovarian Cancer Alliance</p> <p>The Changing Face of Cancer: Progress and Emerging Trends (15 minutes) Rebecca Siegel, American Cancer Society</p> <p>Cultivating Strategic Partnerships in Community Engagement (20 minutes) Karen Winkfield, Meharry-Vanderbilt Alliance Vishal Bhatnagar, FDA Oncology Center of Excellence (<i>participating virtually</i>)</p> <p>Equity in Action: Developing the Infrastructure for Sustainable Models of Cancer Care Delivery (30 minutes) Models of Care Delivery for Rural Patient Populations <ul style="list-style-type: none"> Kathi Mooney, University of Utah <p>Operationalizing Care Delivery Models that Promote Equity and High-Quality Cancer Care in the VA <ul style="list-style-type: none"> Justin List, Veterans Health Administration <p>Delivering Psychosocial Care to Cancer Survivors: Progress Made and Still to Come (10 minutes) Julia Rowland, Smith Center for Healing and the Arts</p> <p>Panel Discussion (30 minutes)</p> </p></p>
12:50 pm	Lunch
1:45 pm	<p>Session 3: Workforce Considerations: Reaching for the Quadruple Aim <i>Co-Moderators</i> Larissa Nekhlyudov, Brigham & Women's Hospital; Dana-Farber Cancer Institute Carolyn Hendricks, Maryland Oncology Hematology</p> <p>Multidisciplinary, Multispecialty Workforce from Diagnosis Onward (15 minutes) Larissa Nekhlyudov, Brigham & Women's Hospital; Dana-Farber Cancer Institute</p> <p>Overview of the Oncology Workforce (10 minutes) Carolyn Hendricks, Maryland Oncology Hematology</p> <p>Workforce Wellness (20 minutes) Mickey Trockel, Stanford University (<i>participating virtually</i>) Ishwaria Subbiah, Sarah Cannon Research Institute</p> <p>Promoting and Sustaining Diversity in the Oncology Workforce (10 minutes) Narjust Florez, Dana-Farber Cancer Institute</p> <p>Education and Training (10 minutes) Chris Friese, University of Michigan</p>

	Delivery System Efficiencies: Opportunities to Leverage Digital Health to Improve Care (10 minutes) Edmondo Robinson, Moffitt Cancer Center (<i>participating virtually</i>) Panel Discussion (45 minutes)
3:45 pm	Break
4:00 pm	Session 4: Cancer Care Delivery: Where We've Been, Where We Are, and Where We Are Going <i>Co-Moderators</i> Justin Bekelman, University of Pennsylvania Cardinale Smith, Mount Sinai Health System A Learning Health System to Transform Care and Health Equity (13 minutes) Catherine Alfano, Northwell Health Value-Based Payment and the Delivery of High-Quality Cancer Care: Lessons Learned and Future Directions (10 minutes) Nancy Keating, Harvard Medical School (<i>participating virtually</i>) Health Insurer Perspectives on Cancer Care Delivery Transformation (10 minutes) Lucy Langer, United Healthcare Community Independent Practice and the Future Cancer Care Delivery (10 minutes) Natalie Dickson, TN Oncology Primary and Specialty Care Integration and Innovation (10 minutes) Kameron Matthews, Cityblock Health (<i>participating virtually</i>) Panel Discussion (65 minutes)
6:00 pm	Adjourn Reception
Friday, October 6, 2023 Eastern Time Zone	
8:30 am	Breakfast and Registration
9:00 am	Welcome and Plans for the Day Patricia Ganz, University of California, Los Angeles
9:05 am	Session 5: Evidence Generation to Inform Oncology Care <i>Co-Moderators</i> Nathan Pennell, Cleveland Clinic Robin Yabroff, American Cancer Society Overview Presentations (30 minutes) Practice-Changing Research Since the IOM Report (10 minutes) <ul style="list-style-type: none"> Julie Gralow, American Society of Clinical Oncology

	<p>Disparities and Underrepresentation in Research Access and Treatment (10 minutes)</p> <ul style="list-style-type: none"> Alex Adjei, Cleveland Clinic (<i>participating virtually</i>) <p>Implementation Science (10 minutes)</p> <ul style="list-style-type: none"> Kate Rendle, University of Pennsylvania (<i>participating virtually</i>) <p>Panel Discussion (90 minutes)</p> <p>Include speakers and:</p> <ul style="list-style-type: none"> Paul Kluetz, FDA Oncology Center of Excellence Robert Miller, ASCO CancerLinQ Wynne Norton, National Cancer Institute (<i>participating virtually</i>) Laurel Pracht, West Valley Ovarian Cancer Alliance Lisa Richardson, Centers for Disease Control and Prevention Claire Snyder, Johns Hopkins School of Medicine and the PROTEUS Consortium
11:05 am	Break
11:20 am	<p>Session 6: Path Forward (Panel Discussion)</p> <p><i>Co-Moderators</i></p> <p>Patricia Ganz, University of California, Los Angeles</p> <p>Hedvig Hricak, Memorial Sloan Kettering Cancer Center</p> <p>Session 1: Patricia Ganz and Laura Levit</p> <p>Session 2: Ishwaria Subbiah and Laurel Pracht</p> <p>Session 3: Larissa Nekhlyudov and Carolyn Hendricks</p> <p>Session 4: Justin Bekelman and Cardinale Smith</p> <p>Session 5: Nathan Pennell and Robin Yabroff</p>
12:30 pm	Adjourn

Workshop Co-Hosts

American Society of Clinical Oncology
National Cancer Policy Forum

Sponsors of the National Cancer Policy Forum

Centers for Disease Control and Prevention

National Institutes of Health/National Cancer Institute

American Association for Cancer Research

American Cancer Society

American College of Radiology

American Society of Clinical Oncology

Association of American Cancer Institutes

Association of Community Cancer Centers

Bristol-Myers Squibb

Cancer Support Community

Flatiron Health

Merck

National Comprehensive Cancer Network

National Patient Advocate Foundation

Novartis Oncology

Oncology Nursing Society

Partners in Health

Pfizer Inc

Sanofi

Society for Immunotherapy of Cancer

We are grateful for the support of our sponsors, which is crucial to the work of the Forum.

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care: A Workshop

Planning Committee Roster

Patricia A. Ganz, MD (Chair)

Distinguished Professor Health Policy &
Management and Medicine
UCLA Fielding School of Public Health
David Geffen School of Medicine at UCLA
Director, Cancer Prevention & Control
Research
Jonsson Comprehensive Cancer Center

Justin E. Bekelman, MD

Professor, Radiation Oncology and
Medical Ethics and Health Policy
Director
Penn Center for Cancer Care Innovation
Abramson Cancer Center
Perelman School of Medicine
University of Pennsylvania

Narjust Florez, MD

Associate Director
The Cancer Care Equity Program
Thoracic Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Associate Editor
JAMA Oncology

**Christopher R. Friese, PhD, RN,
AOCN®**

Elizabeth Tone Hosmer Professor of
Nursing, Health Management & Policy
Director
Center for Improving Patient and
Population Health
University of Michigan

Carolyn Hendricks, MD, FASCO

Medical Oncologist
Maryland Oncology Hematology

Hedvig Hricak, MD, PhD, Dr.h.c^m

Carroll and Milton Petrie Chair
Department of Radiology
Memorial Sloan Kettering Cancer Center
Professor of Radiology, Weill Medical
College of Cornell University
Professor, Gerstner Sloan-Kettering
Graduate School of Biomedical Sciences

Larissa Nekhlyudov, MD, MPH

Internist
Brigham and Women's Hospital
Clinical Director
Internal Medicine for Cancer Survivors
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School

Laurel Pracht, BS

President
West Valley Ovarian Cancer Alliance
Cancer Care Delivery Research Committee
NRG Oncology
Cancer Care Delivery Research Steering
Committee
National Cancer Institute

Nathan Pennell, MD, PhD

Professor, Department of Medicine
Deputy Associate Director for Clinical
Research
Member, Immune Oncology Program
Case Comprehensive Cancer Center
Case Western Reserve University
Medical Oncologist
Department of Hematology and Oncology
Taussig Cancer Center
Cleveland Clinic Cancer Center

Cardinale B. Smith, MD, PhD

Professor of Medicine and Geriatrics and
Palliative Medicine
Icahn School of Medicine at Mount Sinai
Chief Medical Officer
Tisch Cancer Hospital
Vice President of Cancer Clinical Affairs
Chief Quality Officer for Oncology
Director of the Supportive Oncology
Program
Mount Sinai Health System
Associate Director
Community Outreach and Engagement
Tisch Cancer Institute
One Gustave L. Levy Place

Ishwaria M. Subbiah, MD, MS

Medical Oncologist
Palliative Care Physician
Executive Director
Cancer Care Equity and Professional
Wellness
Sarah Cannon Research Institute

Robin Yabroff, PhD

Scientific Vice President
Health Services Research
American Cancer Society

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care: A Workshop

Speaker, Panelist, and Moderator Roster

Alex A. Adjei, MD, PhD, FACP

Chief

Taussig Cancer Institute

M. Frank Rudy and Margaret D. Rudy

Distinguished Chair in Translational

Cancer Research

Cleveland Clinic

Catherine M. Alfano, PhD

Vice President

Cancer Care Management and Research

Northwell Health Cancer Institute

Associate Director

Institute of Health System Science

Feinstein Institutes for Medical Research

Professor, Donald and Barbara Zucker

School of Medicine

Hofstra/Northwell

Justin E. Bekelman, MD

Professor, Radiation Oncology, Medicine,
and Medical Ethics and Health Policy

Director

Penn Center for Cancer Care Innovation

Abramson Cancer Center

Perelman School of Medicine

University of Pennsylvania

Vishal Bhatnagar, MD

Associate Director for Patient Outcomes

Oncology Center of Excellence

U.S. Food and Drug Administration

Beverly Canin

Cancer and Aging Research Group

Fumiko Chino, MD

Assistant Attending in Radiation Oncology

Affordability Working Group Lead

Memorial Sloan Kettering Cancer Center

Natalie R. Dickson, MD

President

Chief Strategy Officer

Tennessee Oncology

Narjust Florez, MD

Associate Director

The Cancer Care Equity Program

Thoracic Oncologist

Dana-Farber Cancer Institute

Assistant Professor of Medicine

Harvard Medical School

Associate Editor

JAMA Oncology

**Christopher R. Friese, PhD, RN,
AOCN®**

Elizabeth Tone Hosmer Professor of

Nursing, Health Management & Policy
Director

Center for Improving Patient and

Population Health

University of Michigan

Patricia A. Ganz, MD

Distinguished Professor Health Policy &
Management and Medicine

UCLA Fielding School of Public Health

David Geffen School of Medicine at UCLA

Director, Cancer Prevention & Control

Research

Jonsson Comprehensive Cancer Center

Julie R. Gralow, MD, FACP, FASCO

Chief Medical Officer

Executive Vice President

American Society of Clinical Oncology

Sarah Greene, MPH

Independent Consultant

Carolyn Hendricks, MD, FASCO

Medical Oncologist

Maryland Oncology Hematology

Hedvig Hricak, MD, PhD, Dr.h.c^m
Carroll and Milton Petrie Chair
Department of Radiology
Memorial Sloan Kettering Cancer Center
Professor of Radiology, Weill Medical
College of Cornell University
Professor
Gerstner Sloan-Kettering Graduate School
of Biomedical Sciences

Nancy L. Keating, MD, MPH
Professor, Health Care Policy and Medicine
Harvard Medical School
Program Leader
Cancer Care Delivery Research Program,
Dana-Farber/Harvard Cancer Center

Heidi D. Klepin MD, MS
Professor
Department of Internal Medicine
Hematology and Oncology
Wake Forest School of Medicine

Paul G. Kluetz, MD
Deputy Director
Oncology Center of Excellence
U.S. Food and Drug Administration

Lucy Langer, MD MSHS
National Medical Director
Oncology & Genomics
United Healthcare

Laura Levit, JD
Senior Director
Research Analysis and Publications
Center for Research and Analytics
American Society of Clinical Oncology

**Justin List, MD, MAR, MSc, FACP
(he/him)**
Director, Health Care Outcomes
Office of Health Equity
Veterans Health Administration
Clinical Instructor
Department of Internal Medicine
Yale School of Medicine

**Kameron L. Matthews, MD, JD,
FAAFP**
Chief Health Officer
Cityblock Health

**Robert S. Miller, MD, FACP, FASCO,
FAMIA (he/him/his)**
Chief Medical Science Officer
CancerLinQ
American Society of Clinical Oncology

Kathi Mooney, PhD, RN
Distinguished Professor
College of Nursing
Co-Lead
Cancer Control and Population Sciences
Huntsman Cancer Institute
University of Utah

Shelley Fuld Nasso, MPP
Chief Executive Officer
National Coalition of Cancer Survivorship

Larissa Nekhlyudov, MD, MPH
Internist
Brigham and Women's Hospital
Clinical Director
Internal Medicine for Cancer Survivors
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School

Wynne E. Norton, PhD
Program Director
Implementation Science
Division of Cancer Control and Population
Sciences
National Cancer Institute

Nathan Pennell, MD, PhD

Professor
Department of Medicine
Deputy Associate Director for Clinical
Research
Member, Immune Oncology Program
Case Comprehensive Cancer Center
Case Western Reserve University
Medical Oncologist
Department of Hematology and Oncology
Taussig Cancer Center
Cleveland Clinic Cancer Center

Lori J. Pierce, MD, FASCO, FASTRO

Professor of Radiation Oncology
Vice Provost
Academic and Faculty Affairs
University of Michigan

Laurel Pracht, BS

President
West Valley Ovarian Cancer Alliance
Cancer Care Delivery Research Committee
NRG Oncology
Cancer Care Delivery Research Steering
Committee
National Cancer Institute

**Katharine A. Rendle, PhD, MSW,
MPH**

Assistant Professor
Department of Family Medicine &
Community Health and Epidemiology
Director, Implementation Science
Penn Center for Cancer Care Innovation
Director, Cancer Implementation Research
Penn Implementation Science Center
Associate Director
Mixed Methods Research Lab
Perelman School of Medicine
University of Pennsylvania

Lisa Richardson MD, MPH

Director
Division of Cancer Prevention and Control
National Center for Chronic Disease
Prevention and Health Promotion
Centers for Disease Control and Prevention

**Edmondo Robinson, MD, MBA, MS,
FACP**

Senior Vice President
Chief Digital Officer
Moffitt Cancer Center
Associate Professor
Department of Oncologic Sciences
Associate Professor
Department of Internal Medicine
Morsani College of Medicine
University of South Florida

**Julia H. Rowland, PhD, FASCO,
FAPOS**

Senior Strategic Advisor
Smith Center for Healing and the Arts

Rebecca Siegel, MPH

Senior Scientific Director
Surveillance Research
American Cancer Society

Cardinale B. Smith, MD, PhD

Professor of Medicine, Geriatrics, and
Palliative Medicine
Icahn School of Medicine
Mount Sinai
Chief Medical Officer
Tisch Cancer Hospital
Vice President, Cancer Clinical Affairs
Chief Quality Officer for Oncology
Director of the Supportive Oncology
Program
Mount Sinai Health System
Associate Director
Community Outreach and Engagement
Tisch Cancer Institute

Claire Snyder, PhD

Professor of Medicine and Oncology
Johns Hopkins School of Medicine
Johns Hopkins Bloomberg School of Public
Health
Program Director
BLOCS: Building Lifestyle, Outcomes, and
Care Services Research in Cancer

Patty Spears, FASCO

Research Patient Advocate
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center

Ishwaria M. Subbiah, MD, MS

Medical Oncologist
Palliative Care Physician
Executive Director
Cancer Care Equity and Professional
Wellness
Sarah Cannon Research Institute

Mickey Trockel, MD, PhD

Director
Evidence Based Innovation
Stanford University School of Medicine
WellMD Center

Karen M. Winkfield, MD, PhD

Executive Director
Meharry-Vanderbilt Alliance
Professor of Radiation Oncology
Vanderbilt University
Professor of Internal Medicine
Meharry Medical College

Robert A. Winn, MD

Director
Virginia Commonwealth University Massey
Cancer Center
Senior Associate Dean, Cancer Innovation
Professor, Pulmonary Disease and
Critical Care Medicine
Lipman Chair in Oncology
School of Medicine
Virginia Commonwealth University
President-Elect
Association of American Cancer Institutes

Robin Yabroff, PhD

Scientific Vice President
Health Services Research
American Cancer Society

Robin Zon, MD, FACP, FASCO

President Elect
American Society of Clinical Oncology

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care: A Workshop

SPEAKER, PANELIST, & PLANNING COMMITTEE BIOSKETCHES



Alex A. Adjei, MD, PhD, FACP
Cleveland Clinic

Alex A. Adjei, MD, PhD, FACP, is Chief of the Cancer Institute and the M. Frank Rudy and Margaret D. Rudy Distinguished Chair in Translational Cancer Research at Cleveland Clinic. In this role, Dr Adjei oversees cancer care and research across all Cleveland Clinic locations in Ohio, Florida, London and Abu Dhabi, UAE.

Dr. Adjei has focused his research on experimental therapeutics, regulatory science and clinical drug development and has led NCI-funded drug development teams. Other research interests include health disparities, global oncology, and pharmacogenetics. Dr Adjei has served on a number of NCI and professional association committees. He was Chair of the NIH Study Section NCCR Clinical Research Review Committee, reviewing CTSAs. He was the President of the Minorities in Cancer Research Council of AACR and a member of the Board of Directors of IASLC, and is currently Faculty Coordinator for Developmental Therapeutics and member of the Gender Medicine Task Force of ESMO. He served on the Committee on Diagnosing and Treating Adult Cancers of the US National Academies of Sciences, Engineering and Medicine in 2019-2020. He is a member of the NCI Board of Scientific Counselors. He has published over 300 peer-reviewed articles. He is editor-in-chief of the Journal of Thoracic Oncology and established JTO Clinical and Research Reports, as the inaugural Editor-in-Chief.

Among numerous awards and honors, Dr. Adjei has received the Adi F. Gazdar Merit Award from the International Association for the Study of Lung Cancer for Distinguished Achievement in Lung Cancer Research and Mentorship, the ESMO Lifetime achievement award, and the ASCO Drug Development Research Professorship for his work in drug development, regulatory science and for his mentorship.




Catherine M. Alfano, PhD
Northwell Health Cancer Institute

Catherine Alfano, PhD, is an international leader in cancer survivorship, cancer rehabilitation, and transdisciplinary team science. At Northwell Health, she leads both clinical care design and research across the health system. Operationally, she develops and oversees the implementation and integration of a high-quality cancer survivorship program for the health system that monitors patients from diagnosis forward, delivering equitable, timely, and effective care. The goal of this effort is to simultaneously improve long-term patient outcomes and experience of care while reducing unnecessary costs. She also oversees the development of a Learning Health System for oncology

where research is embedded in care to facilitate translational research and allow patient data to drive personalized care.

Before joining Northwell, she served as the Vice President of Survivorship at the American Cancer Society where she provided vision and leadership to ACS research, programming, and policy efforts nationwide to improve the lives of cancer survivors. She previously served as the Deputy Director of the National Cancer Institute's Office of Cancer Survivorship where she created funding opportunity announcements to fill gaps in cancer survivorship and transdisciplinary research. Dr. Alfano's research aims to speed the effective translation of research into practice and inform supporting policy to optimize patient outcomes and clinic efficiency, address provider shortages, and decrease healthcare costs. In addition to her roles at Northwell, she has held leadership positions for the American Society of Clinical Oncology, the Society of Behavioral Medicine, and the American Congress of Rehabilitation Medicine.



Justin E. Bekelman, MD
University of Pennsylvania

Dr. Bekelman the founding Director of the Penn Center for Cancer Care Innovation at the Abramson Cancer Center, Professor of Radiation Oncology, Medicine, and Medical Ethics and Health Policy at the Perelman School of Medicine, Faculty in the Center for Health Incentives and Behavioral Economics, and Senior Fellow at the Penn Center for Precision Medicine and the Leonard Davis Institute for Health Economics, all at the University of Pennsylvania. Dr. Bekelman leads research programs to improve the length and quality of life for patients with cancer. His research focuses on health care delivery, payment reform and cancer care transformation, integrating methods from the fields of innovation, epidemiology, clinical trials, health economics and public policy. Dr. Bekelman's research has appeared in high-impact scientific journals and has been featured by media outlets in the United States, Canada, Europe, Asia, and Latin America. His work has been funded by the National Cancer Institute, the American Cancer Society, the Patient-Centered Outcomes Research Institute, the Commonwealth of Pennsylvania, and philanthropic sources. He has served as an advisor to the Centers for Medicare and Medicaid Services (CMS) on cancer care payment reform and innovation. Dr. Bekelman is an elected member of the American Society for Clinical Investigation.


Dr. Bekelman completed his undergraduate studies at Princeton University in the Princeton School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Previously, he was a management consultant at the Kalchas Group, advising senior executives of health care and insurance clients on corporate strategy. Dr. Bekelman also served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.



Vishal Bhatnagar, MD

Oncology Center of Excellence, U.S. Food and Drug Administration

Dr. Vishal Bhatnagar is a medical oncologist/hematologist and the Associate Director for Patient Outcomes in the OCE. His interests include patient reported outcomes, patient preference and incorporation of patient experience in oncology trials. His work focuses on the operational management of the OCE's Patient-Focused Drug Development program. Additionally, Dr. Bhatnagar has a strong clinical interest in multiple myeloma and was previously a clinical reviewer in the Division of Hematology Products. Dr. Bhatnagar received his BA in Political Science and his medical degree at the George Washington University. He completed his internal medicine residency and hematology/oncology fellowship at the University of Maryland.



Beverly Canin

Cancer and Aging Research Group

Beverly Canin was diagnosed with breast cancer in 2000. She has over 20 years' experience as a cancer patient advocate and 10 years as a cancer and aging research partner. She serves or has served on the Board of Directors or advisory committees of national, regional, statewide and international breast cancer and cancer and aging service and advocacy organizations. She is a National Breast Cancer Coalition (NBCC) Project LEAD graduate (class of 2003) and has been a peer reviewer for the Department of Defense, California and Breast Cancer Coalition of Rochester Breast Cancer Research Programs. She has collaborated on research submitted to or funded by the Department of Defense Breast Cancer Research Program (DoDBCRP), NCI, Patient Centered Outcomes Research Institute (PCORI) and the National Institute on Aging (NIA) and co-authored related publications. She has been an advocate member of the Cancer and Aging Research Group (CARG) since 2011. She helped create and chaired for six years Stakeholders for Care in Oncology Research for our Elders (SCOREboard), an advisory group formed under a PCORI grant. Currently, under a 5-year NCI/NIA grant to CARG for development of a national infrastructure for cancer and aging research, she co-chairs SCOREboard's service as a resource for engagement in geriatric oncology research of older cancer patients, their caregivers and patient advocates.



Fumiko Chino, MD

Memorial Sloan Kettering Cancer Center

Fumiko Chino, MD is a cancer researcher, Assistant Attending in Radiation Oncology, and Lead of the Affordability Working Group at Memorial Sloan Kettering Cancer Center. She is also one of the Directors at the Costs of Care group, a NGO working to improve affordability in healthcare and the recipient of the inaugural 2022 ASCO Excellence in Equity Award. Her research is focused on the financial toxicity of cancer

care, survivorship, health care disparities, equity, and access and she has spoken across the US and internationally on equity and the costs of care.



Natalie R. Dickson, MD
Tennessee Oncology

Natalie Dickson holds the positions of President and Chief Strategy Officer and was the former Chief Medical Officer for Tennessee Oncology, PLLC one of the nation's largest community-based oncology practices and a member of the OneOncology network. She has maintained an active Hematology-Oncology practice for over 20 years.

In her leadership role she is a champion for evidenced-based clinical practice, efficient high-quality care, and the optimization of clinical information systems to improve patient safety, patient experience and support consistent clinical performance across 39 clinical sites. She provides strategic and visionary input to transform care delivery and facilitate development of new payment models in partnership with OneOncology and other healthcare organizations. She is dedicated to promoting collaboration and cultivating strong internal and external relationships.

She sits on the board of OneOncology the network of high functioning independent community practices. She previously served as the Chair for OneOncology's OneCouncil, the committee of physician leaders to identify best practices and to leverage the unified clinical, operational and financial platforms to scale these practices across the network to maintain high quality care. A diplomate of the American Board of Internal Medicine, she holds certification for Medical Oncology and Hematology, as well as Internal Medicine. She participates in clinical research and is published in leading medical journals. She maintains associations with multiple medical specialty societies, local and national associations that promote education, advocacy, patient safety and policy changes.

She earned her medical degree at the University of the West Indies, Jamaica. She completed her Internal Medicine residency at the University of Virginia; her Medical Oncology fellowship at Georgetown University, and Hematology fellowship at Vanderbilt University. She earned a Master of Management in healthcare at Vanderbilt University Owen Graduate School of Management. Having called Nashville home for 24 years, she is actively involved in local oncology support groups and her church. She and her husband are the proud parents of three children.



Narjust Florez, MD
Dana-Farber Cancer Institute

Dr. Narjust Florez is originally from Venezuela, she graduated first in her medical school class at the Universidad Catolica Nordestana in the Dominican Republic. She completed her internal medicine residency at Rutgers New Jersey Medical School (selected as the most scholarly resident in the Department of Medicine in 2015 and 2016) and fellowship at the Mayo Clinic in Rochester, Minnesota, where she was Chief Fellow from 2018 -2019. She is a thoracic

medical oncologist and the Associate Director of The Cancer Care Equity Program at Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. In 2022, Dr. Florez also became the first Latina to hold an Associate Editor position in Oncology as the new Associate Editor for Diversity, Equity, and Inclusion at *JAMA Oncology*.

Dr. Florez's clinical interests include targeted therapy for lung cancer and the care of women and young patients with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. Additionally, she is also the principal investigator on other notable studies, including the Fertility and Sexual Health Effects of Immune Checkpoint Inhibitors on young women with Non-small Cell Lung Cancer and Melanoma (FhINCH) Study, The Diagnostic Delays in Lung Cancer (LEAD) Study, and the Young Lung Cancer (YLC) Study, which evaluates the psychosocial needs of young patients with lung cancer. Apart from her clinical interests in lung cancer, she is also a globally acclaimed and highly productive researcher in cancer health disparities, gender and racial discrimination in medical education and medical practice. Dr. Florez is one of the co-founders of the Twitter community #LatinasInMedicine, now composed of about 10,000 members globally. She has received many awards, including the first-ever Mayo Clinic Diversity and Inclusion Champion Award in 2017, the 2018 Resident of the Year Award by the National Hispanic Medical Association, the 2018 Minority Scholar in Cancer Research Award by American Association of Cancer Research, the 2019 Mayo Brothers Distinguished Fellowship Award, the 2020 Rising Star Award by LEAD National Conference for Women in Hematology and Oncology, the 2021 International Association for the Study of Lung Cancer (IASLC) North America Cancer Care Team Award for Outstanding Clinical Care. More recently, she received the 2023 Career Development Award in Racial and/or Ethnic Disparities by the American Society of Clinical Oncology (ASCO), and the 2023 Medical Marvel Award by Newsweek.

In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education. The laboratory's long-term goals are to create a welcoming environment for medical trainees from historically underrepresented groups in medicine while improving the care of vulnerable populations. Members of the Florez Lab are agents of change. Since its foundation, the Florez laboratory has received research funding from several national agencies and published over 50 original studies and editorials.

Dr. Florez has over 115 scientific publications and her work has been published in high impact journals such as the Journal of Clinical Oncology, Nature, Cancer Cell, JAMA Oncology and Lancet Oncology. In 2021, she was awarded the Most Highly Cited Author Award by The Mayo Clinic Proceedings. Her work has been featured in various media outlets including The New York Times, STAT News, Healio, OncLive, Vox News, Business Insider, ASCO Post, ASCO Connection, Doximity, and The Cancer Letter.



Christopher R. Friese, PhD, RN, AOCN®
University of Michigan

Christopher R. Friese is the Elizabeth Tone Hosmer Professor of Nursing at the University of Michigan.

Dr. Christopher R. Friese is a national authority in measuring and improving the quality of cancer care delivery. Over his career, he has led pivotal studies to develop and test strategies to improve outcomes of high-risk care. His research findings were among the first to establish a significant relationship between favorable nurse practice environments and lower surgical mortality. With over 100 peer-reviewed publications, Dr. Friese's research findings have informed clinical practice guidelines, and state and federal health policy.

Dr. Friese spent 2016-2017 as a Robert Wood Johnson Foundation Health Policy Fellow in the United States Senate. A clinical expert in hematological malignancies and advanced cancers, Dr. Friese continues to practice as a staff nurse at the University of Michigan Rogel Cancer Center. In 2021, the President appointed Dr. Friese to a six-year term on the National Cancer Advisory Board, which sets national cancer research policy.



Patricia A. Ganz, M.D. (Chair)
University of California, Los Angeles

Dr. Ganz is Distinguished Professor of Health Policy and Management, in the Fielding School of Public Health, Distinguished Professor of Medicine in the David Geffen School of Medicine at UCLA, and Director of the Center for Cancer Prevention & Control Research at the Jonsson Comprehensive Cancer Center. She teaches Evidence Based Medicine and Organizational Change.

Dr. Ganz received her M.D. from the University of California, Los Angeles, School of Medicine in 1973, and completed post-doctoral training in internal medicine and medical oncology at the UCLA Medical Center. She has been on the faculty of the School of Medicine since 1977, and joined the faculty of the School of Public Health in 1992. Since 1993 she has been the Director of Cancer Prevention and Control Research at the Jonsson Comprehensive Cancer Center. In 1999 she was awarded an American Cancer Society Clinical Research Professorship for “Enhancing Patient Outcomes across the Cancer Control Continuum.” Dr. Ganz was elected to the National Academy of Medicine of the National Academy of Sciences in 2007. She served on the National Cancer Institute Board of Scientific Advisors from 2002-2007 and on the American Society of Clinical Oncology (ASCO) Board of Directors from 2003-2006. She received the American Cancer Society Medal of Honor in 2010.

Dr. Ganz is a pioneer in the assessment of quality of life in cancer patients, and has focused much of her clinical and research efforts in the areas of breast cancer and its prevention. At the Jonsson Comprehensive Cancer Center, she leads the scientific program focused on Cancer Control and Survivorship. Her major areas of research include cancer survivorship and late effects of cancer treatment, cancer in the elderly, and quality of care for cancer patients. She

was the Editor-in-Chief of the Journal of the National Cancer Institute: JNCI from 2017-2022. She has had NIH funding for her research for the past 35 years.

She was a founding member of the National Coalition for Cancer Survivorship (NCCS) in 1986 and has dedicated much of her research career to studying both the acute and late effects of cancer treatment in patients and survivors. She has served on four Institute of Medicine/National Academy of Medicine consensus studies that have focused on the needs of cancer survivors—the 2005 report “From Cancer Patient to Cancer Survivor: Lost in Transition” (Hewitt, Greenfield et al. 2006) and the 2007 report “Cancer Care for the Whole Patient: Meeting Psychosocial Needs.” (Adler and Page 2007) She has played an active role in the dissemination of these report recommendations nationally and internationally. In 2013, she chaired the IOM consensus study report entitled “Delivering High-Quality Cancer Care: Charting a Course for a System in Crisis,” (Levit, Balogh et al. 2013) that has had a major impact on health care policy related to cancer care delivery. Most recently, she served on a consensus study that provided updated information for the Social Security Administration regarding disabilities associated with the treatment of cancer in survivors (Diagnosing and Treating Adult Cancers and Associated Impairments, NSAEM 2021). Her policy work related to quality of care has largely occurred as part of her membership in the IOM National Cancer Policy Forum (2005-2013) where she has played a critical leadership role in numerous workshops and meetings. Her bibliography is extensive with more than 600 peer-reviewed publications, editorials, reviews, and four edited books on evidence-based cancer care, cancer survivorship and quality of care, and breast cancer outcomes.



Julie Gralow, MD, FACP, FASCO
American Society of Clinical Oncology (ASCO)

Dr. Gralow is the Chief Medical Officer and Executive Vice President of ASCO and brings to her role deep expertise in patient care, research, education, and global health. Previously, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington School of Medicine, Professor in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, as well as Director of Breast Medical Oncology at the Seattle Cancer Care Alliance.

Dr. Gralow is strongly committed to advancing equity in cancer care. As founder of the Women’s Empowerment Cancer Advocacy Network (WE CAN), she supports patient advocates in low- and middle-resource countries. In addition, she served as an adjunct professor in the University of Washington’s Department of Global Health, as a member of the University of Washington’s Breast Cancer Equity Initiative, as Medical Director for Women’s Cancer-related Population Health at the University of Washington, and as an advisory council member for the Uganda Cancer Institute’s adult Hematology/Oncology Fellowship Training Program. Dr. Gralow received the ASCO Humanitarian Award in 2018 for her work in empowering women cancer patients and survivors globally. She is a recognized leader in breast cancer clinical research, and has conducted clinical trials in breast cancer prevention, treatment, and survivorship. Dr. Gralow served in leadership roles for the SWOG Cancer Research Network funded by the National Cancer Institute (NCI), including as Vice Chair of the Breast Cancer Committee and Executive Officer of Breast and Lung Cancer.

Before joining ASCO full-time, Dr. Gralow served the Society in a variety of volunteer and leadership roles, including chairing the ASCO Academic Global Oncology Task Force, co-chairing the ASCO Resource Stratified Guideline Advisory Group, and serving on the editorial board of the European Society of Medical Oncology (ESMO)/ASCO Global Curriculum in Medical Oncology. She also has been involved with numerous other nonprofit organizations, including Team Survivor Northwest, an exercise and fitness program for woman cancer survivors which she co-founded in 1995 and serves as Team Physician; a medical advisory committee member for Cierra Sisters African American Support Group; an advisory board member of Global Focus on Cancer; and a Board member of Peace Island Medical Center, a rural access hospital in Washington State.

Dr. Gralow received her bachelor's degree from Stanford University and her medical degree from the University of Southern California School of Medicine. She trained in internal medicine at Brigham and Women's Hospital at Harvard Medical School and completed a medical oncology fellowship at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle.



Sarah M. Greene, MPH
Independent Consultant

Sarah Greene, MPH, is a consultant, researcher, and cancer survivor with expertise in learning health systems, health communication, electronic health data, and patient-centered care. Much of her career has been focused on building productive, sustainable multi-site research networks that conducted applied research on cancer, mental health, aging, and communication. She applies a versatile skillset and intellectual curiosity in the areas of digital health, evidence mobilization, and community engagement, and is a recognized national leader in understanding how to bridge research and healthcare delivery using a learning health systems approach. Her perspectives are deeply informed by her recent experience with a cancer diagnosis and successful treatment.

Ms. Greene's current and recent consulting clients have included the National Academy of Medicine, Trillium Health Partners, NORC, the National Cancer Institute, and Kaiser Permanente. She was the inaugural Executive Director of the Health Care Systems Research Network (HCSRN), a consortium of embedded research centers, where she led all of the organization's activities. Ms. Greene advises several large research institutes, state-based health care improvement organizations, and research networks. Prior to leading the HCSRN, Ms. Greene served as an Associate Director at PCORI, providing intellectual and organizational leadership for PCORI's National Patient-Centered Clinical Research Network, PCORnet®. She held multiple positions at Group Health Cooperative (now Kaiser Permanente Washington), including director, strategy and business development, and senior research associate on the Group Health Research Institute faculty. Throughout her career, Ms. Greene has frequently served in strategic planning, change management, and team development roles, and complements these skills with strong technical capabilities including literature synthesis, survey design, evaluation, and qualitative analysis. An accomplished writer and speaker with more than 170 publications and presentations, she has shared her work at the National Academy of Medicine, American College of Cardiology, American Medical Informatics Association, and

AcademyHealth, among many other organizations. Ms. Greene received both her MPH and a BA in Psychology and Italian from Indiana University and resides in Seattle.



Carolyn Hendricks, MD, FASCO
Maryland Oncology Hematology

Dr. Hendricks specializes in breast cancer and is an active member of a multidisciplinary team focused on breast cancer genetics, screening, and treatment. She provides cutting edge and comprehensive treatment at the local level. Praised for her involvement in clinical trials for breast cancer, she brings knowledge and support to community groups by providing education about breast cancer. Her greatest accomplishments include her ASCO (American Society of

Clinical Oncology) volunteer activities both nationally and internationally in the area of quality cancer care. She received the prestigious ASCO Fellowship Award in June 2018. Dr. Hendricks is known for heightening breast cancer awareness and delivering quality breast cancer care throughout her career.



Hedvig Hricak, MD, PhD, Dr.h.cm
Memorial Sloan Kettering Cancer Center

Dr. Hricak is a diagnostic radiologist and holds the Carroll and Milton Petrie Chair of Radiology at Memorial Sloan Kettering Cancer Center, New York, NY. She is also a member of the Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Professor, Gerstner Sloan Kettering Graduate School of Biomedical Sciences, and Professor of Radiology, Weill Cornell College of Medicine, New York, NY. The hallmark of her research career has been the development, validation, and dissemination of new diagnostic imaging techniques,

particularly for oncology; she is actively engaged in developing evidence-based imaging guidelines and introducing the concept of integrated diagnostics for oncology. For her research accomplishments and her efforts to promote national and international education and collaboration in oncologic imaging, she has won numerous awards, including the David Rall Medal, for Distinguished Leadership, from the National Academy of Medicine; five gold medals; and honorary fellowships or memberships in twenty-two international radiological societies. She holds honorary doctorates from the Ludwig Maximilian University, Munich and the University of Toulouse III, Paul Sabatier, Toulouse, France. Hricak is a member of the National Academy of Medicine (formerly the Institute of Medicine) and a “foreign” member of both the Russian Academy of Sciences and the Croatian Academy of Sciences and Arts. She has served on several national advisory boards and councils, including the National Institutes of Health Board of Scientific Counselors, the Scientific Advisory Board of the National Cancer Institute, the Advisory Council of the National Institute of Biomedical Imaging and Bioengineering, and the Nuclear and Radiation Studies Board, National Academy of Sciences. She has also served as chair, co-chair, or member of several Institute of Medicine/National Academy of Medicine and National Academy of Sciences studies.



Nancy L. Keating, MD, MPH
Harvard Medical School

Nancy L. Keating, MD, MPH, is Professor of Health Care Policy and Medicine at Harvard Medical School and a primary care physician at Brigham and Women's Hospital. Dr. Keating is currently Clinical Lead of the Evaluation Team for the Center for Medicare and Medicaid Service's Oncology Care Model, an alternate payment and delivery model for oncology practices administering chemotherapy. The evaluation is assessing total costs of care, quality of care, health care utilization, patients' experiences, and outcomes for patients in approximately 200 participating practices compared with non-participating practices. In other work, she is studying the impact of financial integration of oncology practices into systems and hospitals and its impact on care delivery. In ongoing work, she is assessing the reliability and consistency of quality and equity measurement across oncology practices caring for individuals with cancer. Previous work has examined patient, physician, and health system factors contributing to the variations in the intensity of end-of-life care for individuals with advanced cancer, and she has recently completed pilot testing of interventions to improve patients' understanding of the goals of chemotherapy and to improve patients' discussions with their clinicians about their preferences and goals of care.

Dr. Keating received her MD degree from the University of Chicago Pritzker School of Medicine, and her MPH degree from the Harvard TH Chan School of Public Health. In 2022, she was awarded the John M. Eisenberg Award for Career Achievement in Research by the Society of General Internal Medicine. She is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. Dr. Keating has been continuously funded by the National Institutes of Health as principal investigator for more than twenty years. She serves as Program Leader of the Dana-Farber Cancer Institute Cancer Care Delivery Research Program and she co-leads a T32 training grant, Training in Oncology Population Sciences, or TOPS. She currently serves as an Associate Editor at the Journal of the National Cancer Institute, a member of the editorial board of the Journal of Geriatric Oncology and Annals of Internal Medicine, and she is member of the National Comprehensive Cancer Center Senior Oncology Guideline Panel.



Heidi D. Klepin, MD, MS
Wake Forest School of Medicine

Dr. Klepin is a Professor in the Department of Internal Medicine, Section on Hematology and Oncology at the Wake Forest School of Medicine. She is a dually trained geriatrician and oncologist with a clinical and research focus on geriatric oncology. She also earned a master's degree in Health Sciences Research from Wake Forest University. Her clinical work focuses on a Geriatric Oncology Clinic, providing cancer care to adults 75 years of age or older. Her scholarly work is dedicated to improving the lives of older adults with cancer. Her research investigates the following themes among older adults with cancer: (1) patient-level characteristics as predictors of treatment outcomes; (2) the impact of chemotherapy on physical, cognitive, and emotional health; and (3) interventions such as exercise to minimize treatment-

associated disability and improve quality of life. She is co-leader of the Cancer and Aging Research Group, member of the Alliance for Clinical Trials in Oncology Cancer in the Older Adult and Health Outcomes Subcommittees, past chair of the American Society of Clinical Oncology Cancer Research Committee, and member of the American Society of Hematology Scientific Affairs Committee.



Paul G. Kluetz, MD

Oncology Center of Excellence, U.S. Food and Drug Administration

Paul Kluetz is a medical oncologist and Deputy Director of the Oncology Center of Excellence (OCE) at the U.S. FDA. In addition to contributing to the strategic leadership and operational oversight of the OCE, he holds a leadership role in the Office of Oncologic Drugs overseeing the regulatory review of solid tumor drug indications within the Center for Drug Evaluation and Research. Dr. Kluetz founded and leads several initiatives including creation and direction

of the OCE's patient-focused drug development program; OCE's real-world evidence program; trial modernization efforts including pragmatic and decentralized trial designs; use of digital health technology; the OCE's Oncology labeling program; and support of the OCE's extramural research portfolio. He remains clinically active, caring for patients and supervising medical residents at the Georgetown University Hospital.



Lucy Langer, MD, MSHS

United Healthcare

Lucy R. Langer, MD, MSHS, is the National Medical Director of Oncology and Genomics at UnitedHealthcare. Dr. Langer earned her medical degree at Stanford University where she also completed her training in internal medicine and served as Chief Resident. She then completed fellowship in hematology and oncology, as well as a master's degree in Health Services Research at the UCLA David Geffen

School of Medicine. Dr. Langer is a graduate of the advanced course in cancer genetics through the City of Hope National Medical Center. Dr. Langer is the co-founder of the US Oncology Genetic Risk Evaluation and Testing (GREAT) Program and served as the US Oncology Medical Director of Cancer Genetics for more than ten years. Under her leadership, the GREAT program developed a robust educational series and a suite of tools essential to patient evaluation and program management. Dr. Langer was instrumental in forging an important industry partnership to unify individual genetics practices on a single database.

Dr. Langer served two terms as the Chair of the US Oncology National Policy Board Executive Committee. She continues to see patients in private practice at Compass Oncology, in Portland, OR, which she led as Practice President for 8 years. As President of Compass Oncology, Dr. Langer oversaw the expansion of team-based care with a robust APP program and development of a social work program; she led a challenging but necessary change in physician compensation; and she oversaw the development of a \$40M cancer center in Tigard, OR. Dr. Langer is a member of several professional organizations, including the American Society of

Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the Oregon Society of Medical Oncology (OSMO), and the American Society of Human Genetics (ASHG).



Laura Levit, JD

American Society of Clinical Oncology

Laura Levit is Senior Director of Research Analysis and Publications in Center for Research and Analytics at the American Society of Clinical Oncology (ASCO). She is the programmatic lead for ASCO's State of Cancer in America series in JCO Oncology Practice and for ASCO's cosponsored workshops with the U.S. Food and Drug Administration. She has worked with volunteer groups to develop ASCO research statements on topics related to the ethics and design of clinical trials.

Prior to joining ASCO, she was a program officer at the Institute of Medicine (IOM, now the National Academy of Medicine) where she served as the study director for the report *Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis* (2013) and staffed the National Cancer Policy Forum. Laura graduated from the University of Virginia School of Law and is a member of the Virginia Bar Association. She completed her undergraduate studies at the College of William and Mary.



Justin List MD, MAR, MSc, FACP (he/him)

Veterans Health Administration

Justin List, MD, MAR, MSc, FACP (he/him/his) is Director of Health Care Outcomes in the Office of Health Equity national program office at the Veterans Health Administration (VHA) where he leads strategies advancing systemwide equity-guided quality improvement and improving health care outcomes. Prior to joining VHA, he was jointly Assistant Vice President in the NYC Health + Hospitals/Office of Ambulatory Care and Population Health and Chief Quality Officer

for NYC Health + Hospitals/Gotham Health, one of the largest Federally Qualified Health Centers, where he also practiced as a primary care internist. Among his roles at NYC Health + Hospitals, he was part of the founding steering committee for its system Equity & Access Council and a system liaison with the American Cancer Society. Prior to NYC Health + Hospitals, he was Director of Clinical & Scientific Affairs in the Bureau of Chronic Disease Prevention and Tobacco Control, NYC Department of Health & Mental Hygiene, overseeing the Cancer Prevention & Control Program, the citywide Public Health Detailing program, and clinical tobacco control. Dr. List has masters level training in ethics as well as in health services research and also trained in the NIH/Fogarty International Clinical Research Scholars program. He completed his internship and residency in the Yale Internal Medicine Primary Care Program and completed his fellowship in the Robert Wood Johnson/VA Clinical Scholars Program at the University of Michigan and VA Ann Arbor Healthcare System. He is a Clinical Instructor in the Department of Internal Medicine, Yale School of Medicine. He has over forty publications, including peer-reviewed articles and book chapters.



Kameron L. Matthews, MD, JD, FAAFP
Cityblock Health

Kameron Leigh Matthews MD, JD, FAAFP is the Chief Health Officer of Cityblock Health, a transformative, value-based healthcare provider integrating medical, behavioral, and social services for Medicaid and dually eligible, low-income Medicare beneficiaries. A board-certified Family Physician, Dr. Matthews has focused her career on marginalized communities, having held multiple leadership roles in correctional medicine, federally qualified health centers, and managed care. Most recently at the Veterans Health Administration, she led transformational efforts focused on integrated, Veteran-centered models of care including the implementation of the MISSION Act of 2018 and the EHR modernization effort. She is an elected member of the National Academy of Medicine where she chairs the Health Policy Fellowships and Leadership Programs Advisory Committee and is a member of the Standing Committee on Primary Care. She is a member of the sixth class of the Aspen Institute's Health Innovators Fellowship. As a passion outside of work, she co-founded and co-direct the Tour for Diversity in Medicine, an initiative seeking to bring premedical enrichment activities to underrepresented minority high school and undergraduate students across the country. She received her bachelor's degree at Duke University, her medical degree at Johns Hopkins University, and her law degree at the University of Chicago. She is originally from Philadelphia, PA and is current located in Washington, DC.



Robert S. Miller, MD, FACP, FASCO, FAMIA
CancerLinQ, American Society of Clinical Oncology

Dr. Miller is a medical oncologist and clinical informaticist who is Chief Medical Science Officer, CancerLinQ®, a health technology platform for oncology developed by the American Society of Clinical Oncology (ASCO) to improve quality of care and health outcomes for all patients with cancer and advance evidence-based research. In his current role, he provides scientific and clinical leadership for all aspects of CancerLinQ's strategic plan and operations, including data, products, and research. He leads the clinical, account management, and quantitative science team at CancerLinQ and serves as primary staff support for the CancerLinQ physician committees. Previously, he was ASCO Vice President for Quality and Guidelines, responsible for clinical practice guidelines, performance measurement, the Quality Oncology Practice Initiative, and quality informatics. Prior to his full-time employment at ASCO, he was Oncology Medical Information Officer at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, where he specialized in the care of patients with breast cancer.



Kathi Mooney, PhD, RN
University of Utah

Dr. Kathi Mooney, co-leads Cancer Control and Population Sciences at the Huntsman Cancer Institute and is a Distinguished Professor in the College of Nursing at the University of Utah. She is a leader in cancer patient reported outcomes, technology-enabled remote symptom monitoring and home-based models of cancer care. Her research focuses on health care delivery and value-based cancer care, integrating methods from the fields of innovation, clinical oncology, and both clinical trials and community-based research methods. Dr. Mooney developed Symptom Care at Home, a comprehensive telehealth platform that remotely monitors and manages patient-reported cancer symptoms at home. She has extended this work to acute and subacute care at home through Huntsman at Home, an oncology hospital at home program where she leads the implementation and evaluation of both the Salt Lake and Rural programs. Her research has been continuously funded by the National Cancer Institute for more than twenty years.



Shelley Fuld Nasso, MPP
National Coalition for Cancer Survivorship

Shelley is Chief Executive Officer of the National Coalition for Cancer Survivorship (NCCS), where she advocates to transform the cancer care system for everyone touched by cancer. NCCS engages in public policy efforts to improve cancer care and empowers cancer survivors and caregivers to be a voice in public policy debates. Prior to joining NCCS in 2013, she led public policy efforts at Susan G. Komen. She is a graduate of Rice University and the Harvard Kennedy School. She advocates in honor of her dear friend, Dr. Brent Whitworth, a beloved physician who died of cancer at the age of 43.



Larissa Nekhlyudov, MD, MPH, FASCO
Brigham and Women's Hospital/Dana-Farber Cancer Institute,
Harvard Medical School

Dr. Larissa Nekhlyudov is a Professor of Medicine at Harvard Medical School and is a practicing primary care physician at the Brigham & Women's Hospital in Boston, Massachusetts. She is also the Clinical Director, Internal Medicine for Cancer Survivors at the Dana-Farber Cancer Institute where she offers clinical care for long term survivors of childhood and adult cancers. Dr. Nekhlyudov is particularly interested in improving the care of cancer survivors and the interplay between primary and oncology care. Her publications (including journal articles, book chapters, and two books), as well as her broad-ranging educational programs, have promoted global awareness among health care providers about the ongoing needs of cancer patients across the care continuum. Dr. Nekhlyudov has been at the forefront of the field of cancer survivorship, nationally and internationally, by leading and participating in the development of policies, clinical guidelines, educational programs, and research.

Dr. Nekhlyudov is an active member of the American Society of Clinical Oncology, the National Comprehensive Cancer Network, and the Society of General Internal Medicine, and is an Executive Member of the Cancer and Primary Care Research International Network (Ca-PRI). She is a member of the National Academies of Sciences, Engineering and Medicine (NASEM) National Cancer Policy Forum. Dr. Nekhlyudov has previously served on several NASEM activities including the *Committee on the Quality of Cancer Care: Addressing the Challenges of an Aging Population* and the *Committee on Diagnosing and Treating Adult Cancers and the planning committees for Long-Term Survivorship Care after Cancer Treatment: A Workshop and Improving the Evidence Base for Treatment Decision-Making for Older Adults with Cancer: A Virtual Workshop*. During her tenure as the Inaugural National Cancer Institute (NCI)-AcademyHealth Visiting Scholar, she developed a framework for quality survivorship care that has now been adapted by the NCI Office of Cancer Survivorship and has led to numerous national and international initiatives. Throughout her career, Dr. Nekhlyudov has been dedicated to teaching and mentoring students, residents, fellows, and faculty. She has also been committed to empowering cancer survivors and caregivers through educational programs.

Dr. Nekhlyudov received her M.D. from the Mount Sinai School of Medicine and completed residency training at Yale-New Haven Hospital/Yale Primary Care Residency Program. She completed the Harvard Medical School Fellowship in General Medicine and Primary Care and received a Master of Public Health degree from the Harvard School of Public Health. Dr. Nekhlyudov has been on faculty at Harvard Medical School since 1999.



Wynne E. Norton, PhD
National Cancer Institute

Wynne E. Norton, Ph.D., is a Program Director in Implementation Science in the Division of Cancer Control and Population Sciences at the National Cancer Institute. Dr. Norton's scientific and programmatic interests include de-implementation of ineffective practices, pragmatic trials of implementation strategies, optimization of cancer care delivery, and methodological issues in implementation science. She contributes to enhancing the rigorous conduct of pragmatic implementation trials through lectures and workshops, and supports activities related to use of validated measures and data sharing across trials and research consortia in implementation science. Dr. Norton serves as an NCI scientific contact for the Dissemination and Implementation Research in Health PARs and is also involved in four NCI Cancer MoonshotSM Initiatives. She serves as a Project Scientist for the Implementation Science Centers for Cancer Control ([ISC3](#)) and contributes implementation science expertise to the Accelerating Colorectal Cancer Screening and Follow-up Through Implementation Science Consortium ([ACCSIS](#)) and the Improving the Management of symPtoMs during And following Cancer Treatment Consortium ([IMPACT](#)).



Nathan Pennell, MD, PhD
Cleveland Clinic Cancer Center

Dr. Pennell is a board certified medical oncologist who joined the staff of the Taussig Cancer Center in 2008. He specializes in the treatment of thoracic malignancies with a focus on lung cancer, and was appointed director of the TCI lung cancer medical oncology program in 2010. He is a professor of medicine at the Cleveland Clinic Lerner College of Medicine. Dr. Pennell's research interests include clinical trials using novel therapies, with a goal of facilitating the movement of new treatments from the laboratory to the clinic.

He received his Ph.D. in neuroscience in 1998 and his M.D. in 2002 from the University of Florida College of Medicine in Gainesville, FL. Dr. Pennell completed his internal medicine residency in 2005 at Brigham and Women's Hospital in Boston, MA. His medical oncology fellowship training was completed in 2007 at the Dana Farber Cancer Institute.



Lori Pierce, MD
University of Michigan

Dr. Lori Pierce attended Duke University School of Medicine and completed a Radiation Oncology residency and chief residency at the Hospital of the University of Pennsylvania. She then was appointed as a Senior Investigator at the National Cancer Institute, National Institutes of Health in Bethesda, MD from 1990-1992. In 1992, Dr. Pierce joined the faculty of the University of Michigan where she is currently Professor with tenure in Radiation Oncology. Since coming to Michigan, she has served as residency director and clinical director in the Department of Radiation Oncology. In August 2005, Dr. Pierce was appointed by the University of Michigan Board of Regents to be Vice Provost for Academic and Faculty Affairs, a position she still holds.

Dr. Pierce has dedicated her career to the treatment of breast cancer patients. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of women treated with radiation for breast cancer who are carriers of a BRCA1/2 breast cancer susceptibility gene. She serves as Director of the Michigan Radiation Oncology Quality Consortium (MROQC), a quality consortium of radiation oncology practices across the state of Michigan that seeks to establish best practices in the treatment of breast and lung cancers. This initiative is funded by Blue Cross Blue Shield of Michigan and Blue Care Network. She is a previous member of the NCI Breast Cancer Steering Committee and previously served on the Steering Committee for the Early Breast Cancer Trialists' Collaborative Group at the University of Oxford. She continues to serve on many U.S. breast cancer boards and committees and was recently selected to be a member of the Breast Cancer Research Foundation Scientific Advisory Board.

Dr. Pierce has published over 220 manuscripts and book chapters and has received numerous awards from the University of Michigan and multiple national organizations. Honors include

receipt of the European Society of Therapeutic Radiology and Oncology travel award, the American Medical Association Women Physician Mentor Award, the American Association for Women Radiologists' Marie Curie Award, the Conquer Cancer Foundation Endowed Women Who Conquer Cancer Mentorship Award, and selection as a Susan G. Komen for the Cure Scholar. Dr. Pierce was elected to the National Academy of Medicine, Class of 2018. She was also selected as the 2019 Woman of the Year by the United Way of Washtenaw County in Michigan. Most Recently, she was the recipient of the 2021 Association of Community Cancer Centers Annual Achievement Award and the 2021 American Society for Radiation Oncology Gold Medal Award. In 2022, she received the Healio Lifetime Disruptor Award and the OncLive Giants of Cancer Care, Community Outreach, Education and Cancer Policy Award. She is the 2023 recipient of the Vivian and Meyer P. Potamkin Foundation Prize for Breast Cancer Research. In 2018, she was elected president-elect of the American Society of Clinical Oncology, the largest organization of oncology professionals in the world, and served as president in 2020-2021. She was Chair of the Society Board during 2021-2022 and currently served as Past President and Chair of the Association Board.



Laurel Pracht, BS
West Valley Ovarian Cancer Alliance

Laurel J Pracht, a Research Patient Advocate for 22 years represents the patient perspective from developing concepts through launch of clinical trials. She is a graduate of the University of Nebraska with dual Bachelors of Science degrees, and has been is member of NRG Oncology, is a research advocate with the National Cancer Institute and NRG Oncology Cooperative Group. She is an advisory board member of various research initiatives in process. Laurel has a particular interest in rural, often underserved populations as well as the emotional and economic burden patients and caregivers encounter due to a cancer diagnosis. She is a 24-year survivor of late-stage ovarian cancer.



Katharine A. Rendle, PhD, MSW, MPH
University of Pennsylvania

Katharine A. Rendle, Ph.D., M.S.W., M.P.H., is an interdisciplinary behavioral and implementation scientist, with training in Anthropology, Social Work, and Epidemiology. She is currently an Assistant Professor of Family Medicine & Community Health and of Epidemiology in the Perelman School of Medicine at the University of Pennsylvania, and the Director of Implementation Science at the Penn Center for Cancer Care Innovation (PC3I) at Abramson Cancer Center. She is also the Director of Cancer Implementation Research at the Penn Implementation Science Center (PISCE@LDI) and Associate Director of the Mixed Methods Research Lab. Dr. Rendle currently leads several NIH-funded implementation trials designed to identify effective, equitable, and sustainable ways to improve cancer screening and treatment domestically and globally.



Lisa C. Richardson, MD, MPH
Centers for Disease Control and Prevention

Lisa C. Richardson, MD, MPH, is Director of the Division of Cancer Prevention and Control (DCPC), the largest unit within the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion. As director of DCPC, she works with partners at the national, state, and local levels to break down barriers to good health and create opportunities for everyone to live a long and healthy life. Under her leadership, DCPC's four foundational programs, the National Breast and Cervical Cancer Early Detection Program, National Program of Cancer Registries, National Comprehensive Cancer Control Program, and Colorectal Cancer Control Program, have helped the cancer control community better understand, prevent and control cancer in all populations. Dr. Richardson also provides guidance for the Division's research agenda that includes the National Cancer Prevention and Control Research Network. A medical oncologist by training, she has authored or coauthored more than 150 peer-reviewed journal articles examining multi-sectoral approaches to improving cancer care access, delivery, and outcomes.



Edmondo Robinson, MD, MBA, MS, FACP
Moffitt Cancer Center

Dr. Robinson leads Moffitt's Center for Digital Health which leverages the tools of IT, Health Data Services, Clinical Informatics and Digital Innovation to expand Moffitt's ecosystem to deliver on consumer-oriented, real-world solutions for clinical practice, research, education, and administrative processes. The Center for Digital Health creates and tests new services, programs, partnerships, and technologies that leverage digital innovations, while challenging the status quo to reduce the cost of care, improve quality, increase access to care, and enhance the patient experience. In addition, he cares for Moffitt patients as part of the Internal and Hospital Medicine Program which includes teaching students and trainees. Previously, Dr. Robinson was the Chief Transformation Officer and Senior Vice President of Consumerism at ChristianaCare, one of the largest health systems in the mid-Atlantic. He was responsible for the transformation of health care delivery to advance population health initiatives and the move from volume-based to value-based care with a special focus on developing and managing ChristianaCare's consumerism and digital strategies.

Dr. Robinson is an associate professor at the University of South Florida's Morsani College of Medicine. He serves as Chair of the National Advisory Council for the Agency for Healthcare Research and Quality and on the Board of Ardent Health. He is also a fellow of the American College of Physicians, a senior fellow of the Society of Hospital Medicine, and an Aspen Institute Health Innovators Fellow. He holds a medical degree from the David Geffen School of Medicine at the University of California, Los Angeles; an MBA with an emphasis in health care management from the Wharton School at the University of Pennsylvania; and a master's degree in health policy research also from the University of Pennsylvania.



Julia Rowland, PhD, FASCO, FAPOS

Smith Center for Healing and the Arts

Dr. Rowland is a long-time clinician, researcher and teacher in the area of psychosocial aspects of cancer. She has worked with and conducted competitively funded research among both pediatric and adult cancer survivors and their family caregivers, and published broadly in psycho-oncology, including co-editing with the late Dr. Jimmie Holland the ground-breaking text, *Handbook of Psychooncology*. Dr. Rowland received her PhD in Developmental Psychology from Columbia

University and completed a post-doctoral fellowship at Memorial Sloan-Kettering Cancer Center in psychosocial oncology. While at MSKCC, where she held joint appointments in pediatrics and neurology, Dr. Rowland helped to develop and was the first Director of the Post-Treatment Resource Program, an innovative resource designed to provide a full range of non-medical services to patients and their families after the end of treatment. In 1990 Dr. Rowland moved to Washington, DC to become founding Director of the Psycho-Oncology Program at Georgetown University and the Lombardi Cancer Center. Nine years later, she was recruited to the National Cancer Institute to become the first, full-time Director of the Office of Cancer Survivorship. During her 18-year tenure, Dr. Rowland helped build the visibility of the Office of Cancer Survivorship and created numerous governmental and non-profit partnerships to advance public awareness about and funding for research addressing the health care and quality of life needs of the growing population of cancer survivors of all ages. Since retiring from the NCI, Dr. Rowland has served as Senior Strategic Advisor at Smith Center for Healing and the Arts, a non-profit health, education and arts organization that provides integrative services and programs to cancer survivors and those who care for and about them. In this role she strives to bring the growing evidence-base for best practices in quality survivorship care to the broader community.



Rebecca Siegel, MPH

American Cancer Society

Rebecca Siegel is a descriptive epidemiologist at the American Cancer Society in Atlanta where she is currently the Senior Scientific Director of Surveillance Research leading a team of four epidemiologists. She is lead author of the annual *Cancer Facts & Figures* and the companion scientific article, *Cancer Statistics*. She has published more than 120 peer-reviewed scientific articles across the cancer continuum to help inform evidence-based cancer prevention and control worldwide, with an emphasis on

colorectal cancer. Her colorectal cancer research portfolio includes a seminal paper published in 2017 that demonstrated a strong birth cohort effect in the recent rise in early-onset cancer implicating environment exposures. This body of work has helped to prompt research initiatives by the National Cancer Institute and Research UK among others and was a catalyst for recommendations lowering the age to begin screening from 50 to 45 by the American Cancer Society in 2018 and the US Preventive Services Task Force in 2021.



Cardinale B. Smith, MD, PhD
Icahn School of Medicine at Mount Sinai

Dr. Smith is Professor of Medicine (Hematology and Medical Oncology) and Professor of Geriatrics and Palliative Medicine at the Icahn School of Medicine at Mount Sinai. She is the Chief Medical Officer for the Tisch Cancer Hospital and Vice President of Cancer Clinical Affairs. In addition, Dr. Smith is Chief Quality Officer for Oncology and Director of the Supportive Oncology Program for the Mount Sinai Health System, and Associate Director for Community Outreach and Engagement at The Tisch Cancer Institute.

Dr. Smith has an active clinical practice in both oncology and palliative medicine. As a member of Mount Sinai's Center for Thoracic Oncology, Dr. Smith treats patients with thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, malignant pleural mesothelioma, and thymoma. In recognition of her excellence in clinical service, teaching and research, Dr. Smith has been the recipient of Mount Sinai's Dr. Solomon Silver Award in Clinical Medicine, the Division of Hematology and Medical Oncology's Richard E. Rosenfeld Award and The Mount Sinai Graduate School Alumni Award. She was selected as one of 40 Inspiring Hospice and Palliative Medicine Leaders by the American Academy of Hospice and Palliative Medicine.

A highly regarded health services research scientist with a robust grant portfolio supported by the National Institutes of Health and the American Cancer Society, Dr. Smith works with her interdisciplinary research team to improve the quality of care for patients with cancer with a focus on health equity, development of novel models of equitable cancer care delivery and doctor-patient communication. She is also a nationally recognized leader in the field of oncology and palliative care. She is the 2023 Chair of the American Society of Clinical Oncology (ASCO) quality symposium, a member of the nominating committee for the ASCO Board of Directors, and past Chair of the Diversity, Equity and Inclusion Committee for the American Academy of Hospice and Palliative Medicine.

Since 2012, Dr. Smith has served as Director for Mount Sinai's OncoTalk program, a part of the national VitalTalk organization, which provides communication skills training for clinicians caring for cancer patients and their families. Dr. Smith believes in empowering patients to participate in their care plans and determine their care preferences.



Claire Snyder, PhD
Johns Hopkins School of Medicine

Claire Snyder, PhD, is Professor of Medicine (Division of General Internal Medicine) and Oncology at the Johns Hopkins School of Medicine, with a joint appointment in Health Policy & Management in the Bloomberg School of Public Health. She is Director of the Johns Hopkins Program for Building Lifestyle, Outcomes, and Care Services Research in Cancer (BLOCS). Dr. Snyder's research focuses on the quality of cancer care, with emphasis in two areas: quality of life for

cancer patients and coordination of care between primary care providers and cancer specialists. She has received competitive, peer-reviewed funding from the National Cancer Institute, American Cancer Society, and Patient-Centered Outcomes Research Institute.

Dr. Snyder has held various leadership positions in international organizations focused on quality-of-life and quality-of-care. Along with Dr. Michael Brundage, she currently leads the PROTEUS Consortium (Patient-Reported Outcomes Tools: Engaging Users & Stakeholders). She is a past president of the International Society for Quality of Life Research. For the American Society of Clinical Oncology (ASCO), she served on the Health Services Committee, Quality of Care Committee, Survivorship Care Planning Task Force, and Patient-Reported Outcomes Panel.

Previously, Dr. Snyder worked at the U.S. National Cancer Institute and edited *Outcomes Assessment in Cancer: Measures, Methods, and Applications* (Cambridge University Press). She began her career in the private sector at Covance Health Economics and Outcomes Services Inc. Dr. Snyder received a BA cum laude in Public Policy Studies with a certificate in Health Policy from Duke University. She received a Master of Health Science in Health Policy in 2000 and a PhD in Health Policy & Management in 2005 from the Johns Hopkins Bloomberg School of Public Health. She is originally from New Orleans, Louisiana, and currently resides in Baltimore, Maryland.



Patty Spears, FASCO

University of North Carolina at Chapel Hill

Ms. Spears is a cancer research patient advocate bringing the experience as an over 20-year breast cancer and recent liver cancer survivor. She has participated in two clinical trials including a HER2 vaccine clinical trial. She is currently working as a patient advocate at the University of North Carolina (UNC) at Chapel Hill, Lineberger Comprehensive Cancer Center (LCCC) where she leads the UNC Lineberger Patient Advocates for Research Council (PARC) and the

UNC Breast SPORE Advocates. At UNC she focuses on communicating research to the public and facilitates the engagement of patient and community advocates with Lineberger researchers. Ms. Spears has been an advocate for the National Clinical Trials Network (NCTN) since 2008, and is currently the Associate Group Chair for Advocacy for the Alliance for Clinical Trials in Oncology and Chair of the Alliance Patient Advocate Committee. She is also a member of NCI's Clinical Trials and Translational Research Advisory Committee (CTAC), Investigational Drug Steering Committee (IDSC), and is currently Co-Chair of the Patient Advocate Steering Committee (PASC). Ms. Spears has also been a volunteer for several national cancer organizations including the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR). She is the recipient of the AACR 2020 Distinguished Public Service Award for Advocacy and the ASCO 2022 Patient Advocate Award and named a Fellow of ASCO. She has a long-standing commitment to patient and community engagement in research.



Ishwaria M. Subbiah, MD, MS
Sarah Cannon Research Institute

Dr. Ishwaria Subbiah is a medical oncologist and palliative care physician and serves as the Executive Director, Cancer Care Equity and Professional Wellness at Sarah Cannon Research Institute (SCRI), Nashville, TN. In this role, Dr. Subbiah focuses on broadening access to cancer clinical trials to all persons with cancer, particularly those previously underrepresented on trials including older adults aged 65 years and above, race and ethnic minority communities, and patients residing in rural areas. Dr. Subbiah leads teams who build system-level enhancements to address barriers to trial participation across SCRI's combined national integrated cancer care network of 1,300 oncology physicians at 250 locations in 24 states, providing care for about 1.4 million people with cancer every year. Dr. Subbiah also leads the organization's healthcare professional well-being program to support multidisciplinary oncology research professionals in the community.

Dr. Subbiah is a globally recognized expert in geriatric oncology, symptom management, palliative care, and healthcare professional well-being. She previously was an Associate Professor in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. With her unique qualifications from having trained in Developmental Therapeutics, Medical Oncology, and Palliative Medicine, Dr. Subbiah has more than a decade of experience leading teams in developing and implementing organization-wide programs to improve cancer care delivery and clinical workplace experience.



Mickey Trockel, MD, PhD
Stanford University

Mickey Trockel is the Director of Evidence Based Innovation for the Stanford University School of Medicine WellMD Center. His development of novel measurement tools has led to growing focus on professional fulfillment as a foundational aim of efforts to promote physician well-being. Dr. Trockel serves as the Scientific Chair of the Professional Wellness Academic Consortium, which is a group of academic medical centers working together to improve physician wellbeing. The consortium sites have adopted the physician wellness assessment system Dr. Trockel and his colleagues have developed, which offers longitudinal data for benchmarking and natural experiment based program evaluation. He is particularly interested in developing and demonstrating the efficacy of interventions designed to promote wellbeing by improving social culture determinants of wellbeing within healthcare organizations.



Karen Winkfield, MD, PhD
Meharry-Vanderbilt Alliance

Dr. Karen Winkfield is an implementation scientist focused on improving health outcomes for underserved populations through community-engaged research and community-based initiatives designed to improve access to healthcare including clinical trials. She obtained her MD and PhD degrees at Duke University and completed residency in radiation oncology at Harvard. Dr. Winkfield's leadership roles have focused on developing bi-directional communication between researchers and community to ensure equitable access to care regardless of race/ethnicity, geographic location or socioeconomic states. She is a thought leader espousing the importance of workforce diversity to improve health equity. In 2021, Dr. Winkfield was appointed by President Biden to the National Cancer Advisory Board.



Robert A. Winn, MD
Virginia Commonwealth University Massey Cancer Center

Robert A. Winn, MD, is the Director of Virginia Commonwealth University (VCU) Massey Cancer Center. He is also senior associate dean for cancer innovation at the VCU School of Medicine, and professor at the Division of Pulmonary Disease and Critical Care Medicine at VCU. His current basic science research focuses on the translational aspects of the role that proliferation pathways and cellular senescence play in lung cancer. As a pulmonologist, Robert is committed to community-engaged research centered on eliminating health disparities. He is a principal investigator on several community-based projects funded by the NIH and National Cancer Institute. Robert holds a BA from the University of Notre Dame and an MD from the University of Michigan Medical School in Ann Arbor. He completed an internship and residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago and a fellowship in pulmonary and critical care medicine at the University of Colorado Health Sciences Center in Denver.



Robin Yabroff, PhD, MBA
American Cancer Society

Robin Yabroff, PhD, is an epidemiologist and Scientific Vice President, Health Services Research, at the American Cancer Society. She conducts research on the economic burden of cancer; patterns of cancer care, including high cost prescription drugs; health insurance benefit design; and patient, provider, and health system factors associated with the quality and value of cancer care.

Dr. Yabroff has more than 20 years of health services research experience and currently has adjunct positions within the Department of Medicine, Johns Hopkins University, and the Rollins School of Public Health, Emory University. Prior to joining the American Cancer Society, she held positions within the Office of Health Policy, Assistant Secretary for Planning and Evaluation (ASPE) in the US Department of Health and Human

Services, the Health Services and Economics Branch of the National Cancer Institute, and the faculty of the Lombardi Cancer Center, Georgetown University. She earned her PhD in epidemiology from the Johns Hopkins School of Public Health and received an MBA from the University of Rochester.

Dr. Yabroff has co-authored over 300 peer-reviewed journal articles and invited editorials, commentaries, and book chapters. She is a Deputy Editor for the *Journal of the National Cancer Institute*, a founding member of the editorial board of the *Journal of Cancer Survivorship*, and a member of the editorial board of the *JCO Oncology Practice*. Dr. Yabroff has received multiple National Institutes of Health Merit Awards for her research leadership and mentorship.




Robin Zon, MD, FACP, FASCO
American Society of Clinical Oncology

Dr. Zon currently serves as the Director of Breast Cancer Oncology at the Cincinnati Cancer Advisors (CCA), a provider of no-cost second opinions to recently diagnosed cancer patients in or near the Greater Cincinnati area. Prior to joining CCA, Dr. Zon served as Past President, and is now Physician Emeritus at Michiana Hematology Oncology in Mishawaka, IN. She formerly served as Medical Director

of Oncology Research at Memorial Hospital and NCI CCOP Associate and then Principal Investigator until 2013 for the Northern Indiana Cancer Research Consortium, the only NCI designated Community Cancer Oncology Program in the state of Indiana. Dr. Zon is an active volunteer for ASCO, most recently being awarded ASCO's Advocate of the Year for her significant advocacy work on behalf of individuals living with cancer and their cancer care teams and was the recipient of ASCO's Distinguished Achievement Award. Dr. Zon is a Past Chair of ASCO's Government Relations Committee, where she provided distinguished leadership in the society's advocacy efforts. She also served on the Board of Directors from 2010 to 2013, along with participating in many other ASCO related responsibilities.

Delivering High-Quality Cancer Care

Charting a New Course for a System in Crisis



In the United States, approximately 14 million people have had cancer and more than 1.6 million new cases are diagnosed each year. However, more than a decade after the Institute of Medicine (IOM) first studied the quality of cancer care, the barriers to achieving excellent care for all cancer patients remain daunting. Therefore, in 2012, the IOM convened a committee of experts to examine the quality of cancer care in the United States and formulate recommendations for improvement. *Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis* presents the committee's findings and recommendations.

A System in Crisis

The committee concludes that the cancer care delivery system is in crisis. Care often is not patient-centered, many patients do not receive palliative care to manage their symptoms and side effects from treatment, and decisions about care often are not based on the latest scientific evidence.

The cost of cancer care also is rising faster than many sectors of medicine—having increased to \$125 billion in 2010 from \$72 billion in 2004—and is projected to reach \$173 billion by 2020. Rising costs are making cancer care less affordable for patients and their families and are creating disparities in patients' access to high-quality cancer care.

There also are growing shortages of health professionals skilled in providing cancer care, and the number of adults age 65 and older—the group most susceptible to cancer—is expected to double by 2030, contributing to a 45 percent increase in the number of people developing cancer. The current care

Care often is not patient-centered, many patients do not receive palliative care to manage their symptoms and side effects from treatment, and decisions about care often are not based on the latest scientific evidence.

delivery system is poorly prepared to address the care needs of this population, which are complex due to altered physiology, functional and cognitive impairment, multiple coexisting diseases, increased side effects from treatment, and greater need for social support.

The committee proposes a conceptual framework for improving the quality of cancer care (see figure). It comprises six interconnected components: (1) engaged patients; (2) an adequately staffed, trained, and coordinated workforce; (3) evidence-based care; (4) learning health care information technology (IT); (5) translation of evidence into clinical practice, quality measurement and performance improvement; and (6) accessible and affordable care.

Engaging Patients, Developing a Coordinated Workforce


In a high-quality cancer care delivery system, cancer care teams should support all patients in making informed medical decisions by providing patients and their families with understandable information at key decision points on such matters as cancer prognosis, treatment benefits and

harms, palliative care, psychosocial support, and costs of care. To reach this goal, the committee recommends that the federal government work with other stakeholders to improve the development and dissemination of this critical information, using decision aids when possible. And professional educational programs should provide cancer care team members with formal, comprehensive training in communication.

Patients with advanced cancer should receive end-of-life care consistent with their needs, values, and preferences. This will require cancer care teams to revisit and implement patients' advance care plans—which detail the type of care patients would want to receive if they become unable to speak for themselves—and to place a primary emphasis on palliative care, psychosocial support, and timely referral to hospice for end-of-life care.

High-quality cancer care is provided by diverse teams of professionals. The cancer care team, in coordination with primary/geriatrics teams and specialist care teams, should implement patients' care plans and deliver comprehensive, efficient, and patient-centered care. To promote such teams, federal and state legislative and regulatory bodies should eliminate reimbursement and scope-of-practice barriers to

FIGURE: A High-Quality Cancer Care Delivery System



Cancer care teams helping those with advanced cancer should provide patients with end-of-life care consistent with their needs, values, and preferences.

team-based care, and academic institutions and professional societies should develop interprofessional education programs to train the workforce in team-based cancer care.

Moreover, it is critical that cancer care delivery organizations require members of cancer care teams to have the necessary skills to deliver high-quality cancer care, as demonstrated through training, certification, or credentials.

Evidence-Based Care and Improved Information Technology

Clinical research that gathers evidence of the benefits and harms of various treatment options is an essential part of a high-quality cancer care system. Patients, in consultation with their care teams, could use this information to make treatment decisions that are consistent with their needs, values, and preferences. Improving the evidence base will require expanding the breadth and depth of data collected on cancer interventions, including more data on older adults and patients with multiple chronic diseases, as well as more data on patient-reported outcomes, patient characteristics, and health behaviors.

A learning health care IT system would enable real-time analysis of data from cancer patients in a variety of care settings to improve knowledge and inform medical decisions. This IT system would collect and analyze data from clinical practice, implement changes to improve care, evaluate the outcomes of these changes, and generate new hypotheses to test and implement. Many of the elements for a learning health care IT system—

such as electronic health records and cancer registries—already are in place, but these elements often are not implemented or integrated in a way that creates a true learning system. The committee recommends that professional organizations and the Department of Health and Human Services (HHS) develop the necessary components of a learning health care IT system.

Measuring the Quality of Care

In order to continue to advance the high-quality cancer care delivery system, measurement and assessment of progress in improving the delivery of cancer care, public reporting of information gathered, and development of innovative strategies to facilitate performance improvement will be needed. To reach this goal, the committee recommends the development of a national quality reporting program for cancer care. HHS should work with professional societies to create and implement a formal long-term strategy for publicly reporting quality measures for cancer care. They also should prioritize, fund, and direct the development of meaningful quality measures for cancer care with a focus on outcome measures, as well as implement the infrastructure for public reporting.

Accessible and Affordable Care

A high-quality cancer care delivery system should be accessible to all patients, including vulnerable and underserved populations. This system



Committee on Improving the Quality of Cancer Care: Addressing the Challenges of an Aging Population

Patricia A. Ganz (Chair)
Distinguished University
Professor, University of
California, Los Angeles Schools
of Medicine & Public Health;
and Director, Cancer Prevention
& Control Research, Jonsson
Comprehensive Cancer Center

Harvey Jay Cohen
Walter Kempner Professor of
Medicine, and Director, Center
for the Study of Aging and
Human Development, Duke
University Medical Center

Timothy J. Eberlein
Bixby Professor and Chair,
Department of Surgery,
Washington University School
of Medicine; Spencer T. and
Ann W. Olin Distinguished
Professor; and Director,
Siteman Cancer Center at
Barnes-Jewish Hospital,
Washington University School
of Medicine

Thomas W. Feeley
Helen Shafer Fly Distinguished
Professor of Anesthesiology,
Head, Institute for Cancer Care
Innovation, and Head, Division
of Anesthesiology and Critical
Care, The University of Texas
MD Anderson Cancer Center

Betty Ferrell
Professor and Research
Scientist, City of Hope National
Medical Center

James A. Hayman
Professor, Department of
Radiation Oncology, University
of Michigan

Katie B. Horton
Research Professor, George
Washington University, School
of Public Health and Health
Services

Arti Hurria
Associate Professor, and
Director, the Cancer and Aging
Research Program, City of
Hope

Mary S. McCabe
Director, Survivorship Program,
and Lecturer, Division of
Medical Ethics, Weill Medical
College, Memorial Sloan-
Kettering Cancer Center

Larissa Nekhlyudov
Associate Professor,
Department of Population
Medicine, Harvard Medical
School, and Internist,
Department of Medicine,
Harvard Vanguard Medical
Associates

Mary D. Naylor
Marian S. Ware Professor in
Gerontology, and Director,
New Courtland Center for
Transitions and Health,
University of Pennsylvania,
School of Nursing

Michael N. Neuss
Chief Medical Officer, and
Professor, Department of
Medicine, Vanderbilt-Ingram
Cancer Center, Vanderbilt
University Medical Center

Noma L. Roberson
Cancer Research Scientist,
Roswell Park Cancer Institute
(Retired)

Ya-Chen Tina Shih
Associate Professor, Section of
Hospital Medicine, and Director,
Program in the Economics
of Cancer, Department of
Medicine, The University of
Chicago

George W. Sledge, Jr.
Chief of Oncology, Department
of Medicine, Stanford
University

Thomas J. Smith
Director and Harry J. Duffey
Family Professor of Palliative
Medicine and Professor of
Oncology, Johns Hopkins
School of Medicine

Neil Wenger
Professor, University of
California, Los Angeles School
of Medicine

Study Staff

Laura Levit
Study Director

Erin Balogh
Associate Program Officer

Pamela Lighter
Research Assistant

Michael Park
Senior Program Assistant

Patrick Burke
Financial Associate

Sharyl Nass
Director, National Cancer
Policy Forum

Roger Herdman
Director, Board on Health Care
Services

Study Sponsors

AARP

American Cancer Society

American College of Surgeons, Commission on Cancer

American Society for Radiation Oncology

American Society of Clinical Oncology

American Society of Hematology

California HealthCare Foundation

Centers for Disease Control and Prevention

LIVESTRONG

National Cancer Institute - National Institutes of Health

National Coalition for Cancer Survivorship


Oncology Nursing Society

Susan G. Komen for the Cure®

should also reward cancer care teams for providing patient-centered, high-quality care and eliminating wasteful interventions.

The committee recommends that HHS develop a national strategy that leverages existing community interventions to provide accessible and affordable cancer care. To accomplish this, HHS should support the development of innovative programs, identify and disseminate effective community interventions, and provide ongoing support to successful community interventions. In addition, payers should design and evaluate new payment models that encourage cancer care teams to provide care that is based on the best available evidence and aligns with their patients' needs, values, and preferences. If evaluations of specific payment models demonstrate increased quality and affordability, payers should rapidly transition from fee-for-service reimbursements to new payment models.

Conclusion

Changes across the board urgently are needed to improve the quality of cancer care. All participants and stakeholders, including cancer care teams, patients and their families, researchers, quality metrics developers, and payers, as well as HHS, other federal agencies, and industry, must reevaluate their current roles and responsibilities in cancer care and work together to develop a higher quality cancer care delivery system. By working toward this shared goal, the cancer care community can improve the quality of life and outcomes for people facing a cancer diagnosis. 

INSTITUTE OF MEDICINE

OF THE NATIONAL ACADEMIES

Advising the nation • Improving health

500 Fifth Street, NW

Washington, DC 20001

TEL 202.334.2352

FAX 202.334.1412

www.iom.edu

The Institute of Medicine serves as adviser to the nation to improve health.

Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policy makers, health professionals, the private sector, and the public.

Copyright 2013 by the National Academy of Sciences. All rights reserved.



ABOUT THE FORUM



The National Cancer Policy Forum serves as a trusted venue in which experts can identify emerging high-priority policy issues in cancer research and cancer care and work collaboratively to examine those issues through convening activities focused on opportunities for action. The Forum provides a continual focus within the National Academies on cancer, addressing issues in science, clinical medicine, public health, and public policy that are relevant to the goal of reducing the cancer burden, through prevention and by improving the care and outcomes for those diagnosed with cancer. Forum activities inform the cancer community and the public about critical policy issues through workshops and published reports. The Forum has members with a broad range of expertise in cancer, including patient advocates, clinicians, and basic, translational, and clinical scientists. Members represent patients, federal agencies, academia, professional organizations, nonprofits, and industry.

The Forum has addressed a wide array of topics, including:

- enhancing collaborations to accelerate research and development;
- improving the quality and value of care for patients who have been diagnosed with or are at risk for cancer;
- developing tools and technologies to enhance cancer research and care; and
- examining factors that influence cancer incidence, mortality, and disparities.

nationalacademies.org/NCPF

To receive updates on the National
Cancer Policy Forum, visit

nationalacademies.org/NCPF

#NatlCancerForum

**NATIONAL
ACADEMIES** Sciences
Engineering
Medicine

Upcoming and Recent Workshops

Biological Effectors of Social Determinants of Health in Cancer: Identification and Mitigation

March 20-21, 2024

Biological effectors of social determinants of health (SDOH) interact and impact cancer risk, treatment outcomes, and health equity. Workshop presentations and discussions will consider opportunities to advance health equity in cancer by identifying promising avenues for future research, as well as policies and interventions aimed at mitigating the negative impacts of the SDOH in cancer.

[Workshop website in development](#)

Optimizing Public-Private Partnerships for Clinical Cancer Research

Collaborative workshop convened by:

National Cancer Policy Forum

Forum on Drug Discovery, Development, and Translation

October 17-18, 2023

Public-private partnerships have the potential to more effectively leverage public funding and resources, increase the breadth and depth of research, and effect a more rapid translation from basic discoveries to public health applications. Industry, government, nonprofit, and academic organizations could each make important and unique contributions to this endeavor. This workshop will examine opportunities to enhance and foster public-private partnerships for clinical cancer research and consider lessons learned from examples of public-private collaborations in oncology or other fields that have helped to advance clinical research and improve patient outcomes.

[Workshop website](#)

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care

Collaborative workshop co-hosted by:

National Cancer Policy Forum

American Society of Clinical Oncology

October 5-6, 2023

This year marks the 10-year anniversary of the Institute of Medicine (IOM) report, *Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis*, and the ability of the cancer care delivery system to provide high-quality cancer care to all patients remains elusive. This workshop—co-sponsored by the National Cancer Policy Forum and the American Society of Clinical Oncology—is an opportunity for the cancer care community to discuss persistent barriers to achieving excellent and equitable cancer care for all, and additional actions that could be taken to implement the 2013 recommendations. Workshop presentations and discussions may also identify aspects of cancer care that have changed over the past decade and where new strategies are needed to improve the quality of care.

[Workshop website](#)

Developing a Multidisciplinary and Multispecialty Workforce for Patients with Cancer, from Diagnosis to Survivorship

Collaborative workshop convened by:

National Cancer Policy Forum

Global Forum on Innovation in Health Professional Education

July 17-18, 2023

Patients living with and beyond cancer often require care from a wide range of clinicians as they navigate cancer diagnosis, treatment, and survivorship care. A multispecialty and multidisciplinary workforce is critical to ensuring that all patients with cancer receive high-quality care.

This workshop examined opportunities to improve equitable access to multispecialty, multidisciplinary care for patients living with and beyond cancer. Workshop presentations and discussions focused on strategies to expand and strengthen the multispecialty and multidisciplinary workforce, particularly in underserved areas; approaches for enhancing health professional education across the spectrum of non-oncology clinicians to include best practices for the care of patients with cancer; opportunities for collaboration and information-sharing among members of a patient's health care team across specialties and disciplines; payment and care delivery models to facilitate coordination and collaboration; and opportunities to strengthen the evidence base about the array of adverse effects of cancer and cancer treatment on patient outcomes, as well as interventions aimed at mitigating these effects.

[Workshop videos and presentations](#)

The Impact of the Dobbs Decision on Cancer Care Webinar Series

The National Cancer Policy Forum hosted a webinar series to discuss the downstream effects of the U.S. Supreme Court ruling, *Dobbs v. Jackson Women's Health Organization*, on access to reproductive health care in the context of cancer care.

- **How Abortion Restrictions Affect Patients and Care Delivery | July 11, 2023**
- **Health System and Workforce Effects | July 25, 2023**
- **Ethical, Legal, & Social Implications | August 31, 2023**

[Webinar Series Website](#)

Recent Workshops

The Potential Contribution of Cancer Genomics Information to Community Investigations of Unusual Patterns of Cancer

Collaborative workshop convened by:

National Cancer Policy Forum
Roundtable on Genomics and Precision Health

April 13, 2023

This workshop examined the opportunities to apply genomic and epigenomic biomarkers of environmental exposures associated with unusual patterns of cancer, particularly in pediatric populations. The workshop was sponsored by the Division of Environmental Health Science and Practice in the National Center for Environmental Health at the Centers for Disease Control and Prevention and was convened to provide background information to assist the CDC in revising their [Guidelines for Examining Unusual Patterns of Cancer and Environmental Concerns](#).

[Workshop videos and presentations](#)
[Proceedings](#)

Incorporating Integrated Diagnostics into Precision Oncology Care

Collaborative workshop convened by:

National Cancer Policy Forum
Computer Science and Telecommunications Board
Board on Human-Systems Integration

March 6-7, 2023

Innovations in the diagnostic specialties have the potential to reshape cancer diagnosis and enable precision therapy. Spurred by advances in informatics, there are opportunities to combine information from imaging, pathology, and molecular testing. Multidisciplinary collaboration among pathologists, radiologists, and oncologists supplemented by machine-learning based tools could facilitate a more precise understanding of a patient's diagnosis, and what treatment strategies may be most effective to improve outcomes. Integrated diagnostics may also improve patient access to subspecialty expertise, particularly in community-based settings of cancer care. This workshop convened members of the cancer community better define the purpose, goals, and components of integrated diagnostics.

[Workshop videos and presentations](#)

Addressing Resistance in the Development of Cancer Immune Modulator Therapeutics

Collaborative workshop convened by:

National Cancer Policy Forum
Forum on Drug Discovery, Development, and Translation

November 14-15, 2022

Many patients who initially respond to immunotherapy treatment may develop resistance to treatment over time. The reasons for the development of resistance are not fully understood, and resistance continues to pose a major threat to further advances in the field of immunotherapy for cancer treatment. This workshop gave participants in the cancer research and cancer care an opportunity to examine the current challenges related to resistance to immunotherapies and to discuss potential policy options that could help overcome these challenges.

[Workshop videos and presentations](#)

Advancing Progress in Cancer Prevention and Risk Reduction

June 27-28, 2022

This workshop considered the current state of knowledge on risk factors for cancer and best practices for cancer prevention and risk reduction. Workshop sessions focused on strategies to implement population-based and clinic-based prevention, with exemplar programs in both settings. Participants also examined opportunities to spur progress in cancer prevention and risk reduction.

[Workshop videos and presentations](#)
[Proceedings](#)

Family Caregiving for People With Cancer and Other Serious Illnesses

Collaborative workshop convened by:

National Cancer Policy Forum
Roundtable on Quality Care for People with Serious Illness
Forum on Aging, Disability, and Independence

May 16-17, 2022

This workshop used cancer as a lens to examine issues that affect family caregivers for people with serious illnesses. Presentations and discussions included: strategies to better capture, understand, and act on family caregiver input and experience to improve patient care and to support family caregivers; research and policy opportunities to better support family caregiving; and strategies to better embed a health equity focus in family caregiving research, policy and practice.

[Workshop videos and presentations](#)
[Proceedings](#)

FORUM SPONSORS

- Centers for Disease Control and Prevention
- National Institutes of Health/National Cancer Institute
- American Association for Cancer Research
- American Cancer Society
- American College of Radiology
- American Society of Clinical Oncology
- Association of American Cancer Institutes
- Association of Community Cancer Centers
- Bristol-Myers Squibb
- Cancer Support Community
- Flatiron Health
- Merck
- National Comprehensive Cancer Network
- National Patient Advocate Foundation
- Novartis Oncology
- Oncology Nursing Society
- Partners in Health
- Pfizer Inc
- Sanofi
- Society for Immunotherapy of Cancer

MEMBERSHIP OF THE FORUM

Robert A. Winn, M.D. (Chair)
Virginia Commonwealth University

Peter C. Adamson, M.D.
Sanofi

Justin E. Bekelman, M.D.
University of Pennsylvania

Smita Bhatia, M.D., M.P.H.
University of Alabama at Birmingham

Gideon Blumenthal, M.D.
Merck

Chris Boshoff, M.D., Ph.D.
Pfizer Inc

Otis W. Brawley, M.D.
Johns Hopkins University

Robert W. Carlson, M.D.
National Comprehensive Cancer Network

Hillary Cavanagh, M.A.
Centers for Medicare & Medicaid Services

Christina Chapman, M.D.
Baylor College of Medicine

Gwen Darien, B.A.
National Patient Advocate Foundation

James H. Doroshow, M.D.
National Cancer Institute

S. Gail Eckhardt, M.D., FASCO
Baylor College of Medicine

Christopher R. Friese, Ph.D., R.N., AOCN®
University of Michigan

Stanton L. Gerson, M.D.
Case Western Reserve University

Scarlett Lin Gomez, M.P.H., M.D.
University of California, San Francisco

Julie R. Gralow, M.D., FACP, FASCO
American Society of Clinical Oncology

Roy S. Herbst, M.D., Ph.D.
Yale University

Hedvig Hricak, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

Chanita Hughes-Halbert, Ph.D.
University of Southern California

Roy A. Jensen, M.D.
The University of Kansas; Association of American Cancer Institutes

Randy A. Jones, Ph.D., R.N., FAAN
University of Virginia

Beth Y. Karlan, M.D.
University of California, Los Angeles

Samir N. Khleif, M.D.
Georgetown University; Society for Immunotherapy of Cancer

Scott M. Lippman, M.D.
University of California, San Diego

Elena Martinez, Ph.D.
University of California, San Diego

Larissa Nekhlyudov, M.D., M.P.H.
Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School

Randall Oyer, M.D.
University of Pennsylvania; Penn Medicine Lancaster General Health; Association of Community Cancer Centers

Cleo A. Ryals, Ph.D.
Flatiron Health

Richard L. Schilsky, M.D., FASCO
ASCO TAPUR Study; University of Chicago

Julie Schneider, Ph.D.
Oncology Center of Excellence, Food and Drug Administration

Susan M. Schneider, Ph.D., R.N., AOCN®
Duke University

Lawrence N. Shulman, M.D., MACP, FASCO
University of Pennsylvania

Heidi Smith, M.H.S., B.A.
Novartis Pharmaceuticals

Katrina Trivers, Ph.D., M.S.P.H.
Centers for Disease Control and Prevention

Robin Yabroff, Ph.D.
American Cancer Society

FORUM STAFF

Sharyl Nass, Ph.D.
Forum Co-Director
Senior Director, Board on Health Care Services

Erin Balogh, M.P.H.
Forum Co-Director

Jennifer Zhu, M.S.
Associate Program Officer

Emma Wickland, M.P.H.
Research Associate

Anna Adler, B.S.
Senior Program Assistant

Chidinma Chukwurah, B.S.
Senior Program Assistant

Torrie Brown, B.A.
Program Coordinator

Julie Wiltshire, B.S.
Senior Finance Business Partner


Health and Medicine Division Board on Health Care Services

NATIONAL ACADEMIES Sciences
Engineering
Medicine
The National Academies provide independent, trustworthy advice that advances solutions to society's most complex challenges.
www.nationalacademies.org



NATIONAL CANCER POLICY FORUM

WORKSHOP PROCEEDINGS AND RELATED PUBLICATIONS



WORKSHOP PROCEEDINGS

2023

Incorporating Integrated Diagnostics into Precision Oncology Care (In Process)
Addressing Resistance in the Development of Cancer Immune Modulator Therapeutics (In Process)
The Potential Contribution of Cancer Genomics Information to Community Investigations of Unusual Patterns of Cancer: Proceedings of a Workshop
Advancing Progress in Cancer Prevention and Risk Reduction: Proceedings of a Workshop
Realizing the Potential of Genomics across the Continuum of Precision Health Care: Proceedings of a Workshop

2022

Family Caregiving for People with Cancer and Other Serious Illnesses: A Workshop
Innovation in Electronic Health Records for Cancer Care, Research, and Surveillance: A Workshop
Promoting Health Equity in Cancer Care: Proceedings of a Workshop
The Role of Companion Animals as Sentinels for Predicting Environmental Exposure Effects on Aging and Cancer Susceptibility in Humans: Proceedings of a Workshop
Innovation in Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: Proceedings of a Workshop
Impact of the Affordable Care Act on Cancer Prevention and Cancer Care: Proceedings of a Workshop

2021

Addressing the Adverse Consequences of Cancer Treatment: Proceedings of a Workshop
Opportunities and Challenges for Using Digital Health Applications in Oncology: Proceedings of a Workshop
Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer: Proceedings of a Workshop— in Brief
Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening: Proceedings of a Workshop
Drug Research and Development for Adults Across the Older Age Span: Proceedings of a Workshop

2020

Reflections on Sharing Clinical Trial Data: Challenges and a Way Forward: Proceedings of a Workshop
Applying Big Data to Address the Social Determinants of Health in Oncology: Proceedings of a Workshop
Health Literacy and Communication Strategies in Oncology: Proceedings of a Workshop
Enhancing Scientific Reproducibility in Biomedical Research Through Transparent Reporting: Proceedings of a Workshop

To receive updates on the
National Cancer Policy Forum, visit:

nationalacademies.org/NCPF

#NatlCancerForum

NATIONAL
ACADEMIES
Sciences
Engineering
Medicine



WORKSHOP PROCEEDINGS

2019

Developing and Sustaining an Effective and Resilient Oncology Careforce: Proceedings of a Workshop
 Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop
 Improving Cancer Diagnosis and Care: Clinical Application of Computational Methods in Precision Oncology: Proceedings of a Workshop

2018

Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies: Proceedings of a Workshop
 Establishing Effective Patient Navigation Programs in Oncology: Proceedings of a Workshop
 Long-Term Survivorship Care After Cancer Treatment: Proceedings of a Workshop

2017

The Drug Development Paradigm in Oncology: Proceedings of a Workshop
 Cancer Care in Low-Resource Areas: Cancer Treatment, Palliative Care, and Survivorship Care: Proceedings of a Workshop
 Implementation of Lung Cancer Screening: Proceedings of a Workshop
 Incorporating Weight Management and Physical Activity Throughout the Cancer Care Continuum: Proceedings of a Workshop

2016

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop
 Cancer Care in Low-Resource Areas: Cancer Prevention and Early Detection: Workshop Summary
 Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology: Workshop Summary

2015

Comprehensive Cancer Care for Children and Their Families: Summary of a Joint Workshop by the Institute of Medicine and the American Cancer Society
 Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies: Workshop Summary
 Assessing and Improving the Interpretation of Breast Images: Workshop Summary
 Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary

2014


Ensuring Patient Access to Affordable Cancer Drugs: Workshop Summary
 Contemporary Issues for Protecting Patients in Cancer Research: Workshop Summary

2013

Identifying and Addressing the Needs of Adolescents and Young Adults with Cancer: Workshop Summary
 Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary
 Sharing Clinical Research Data: Workshop Summary
 Delivering Affordable Cancer Care in the 21st Century: Workshop Summary
 Reducing Tobacco-Related Cancer Incidence and Mortality: Workshop Summary

2012

The Role of Obesity in Cancer Survival and Recurrence: Workshop Summary
 Informatics Needs and Challenges in Cancer Research: Workshop Summary
 Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary



WORKSHOP PROCEEDINGS

2011

Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary
Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care: Workshop Summary
The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care
Nanotechnology and Oncology: Workshop Summary

2010

Direct-to-Consumer Genetic Testing (with the National Research Council): Summary of a Workshop
Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary
A Foundation for Evidence-Driven Practice: A Rapid Learning System for Cancer Care: Workshop Summary
Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary

2009

Assessing and Improving Value in Cancer Care: Workshop Summary
Ensuring Quality Cancer Care Through the Oncology Workforce: Sustaining Care in the 21st Century:
Workshop Summary
Multi-Center Phase III Clinical Trials and the NCI Cooperative Group Program: Workshop Summary

2008




Implementing Colorectal Cancer Screening: Workshop Summary
Improving the Quality of Cancer Clinical Trials: Workshop Summary

2007

Cancer-Related Genetic Testing and Counseling: Workshop Proceedings
Cancer in Elderly People: Workshop Proceedings
Implementing Cancer Survivorship Care Planning: Workshop Summary

2006

Effect of the HIPAA Privacy Rule on Health Research: Proceedings of a Workshop
Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: Workshop Summary



RELATED WORK

CONSENSUS STUDY REPORTS BUILDING ON NCPF WORK

Childhood Cancer and Functional Impacts Across the Care Continuum (2021)

Report: nap.edu/catalog/25944

Diagnosing and Treating Adult Cancers and Associated Impairments (2021)

Report: nap.edu/catalog/25956

Guiding Cancer Control:
A Path to Transformation (2019)

Report: nap.edu/catalog/25438

Making Medicines Affordable:
A National Imperative (2017)

Report: nap.edu/catalog/24946

Biomarker Tests for Molecularly Targeted Therapies:
Key to Unlocking Precision Medicine (2016)

Report: nap.edu/catalog/21860

Ovarian Cancers: Evolving Paradigms in Research and Care (2016)

Report: nap.edu/catalog/21841

Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis (2013)

Report: nap.edu/catalog/18359

Evolution of Translational Omics: Lessons Learned and the Path Forward (2012)

Report: nap.edu/catalog/13297

A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program (2010)

Report: nap.edu/catalog/12879

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (2010)

Report: nap.edu/catalog/12869

Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research (2009)

Report: nap.edu/catalog/12458

Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment (2007)




Report: nap.edu/read/11892

INDIVIDUALLY AUTHORED PUBLICATIONS BUILDING ON NCPF WORK

Independent, individually authored articles arising from NCPF workshops—and consensus studies building on NCPF work—include:

2022

- Bono, K. and N. L. Keating. 2022. Addressing social determinants of health: Now is the time. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac137/6705076?searchresult=1>.
- Bradley, C. J., S. Kitchen, S., Bhatia, J., Bynum, G., Darien, J. L., Lichtenfeld, R., Oyer, L. N., Shulman, and L. Kennedy Sheldon. 2022. Policies and practices to address cancer's long-term adverse consequences. *Journal of the National Cancer Institute*. 114(8):1065-1071. <https://academic.oup.com/jnci/article-abstract/114/8/1065/6570605?redirectedFrom=fulltext>.
- Davidson, N. E., K. E. Knudsen, S. Fuld Nasso, R. Oyer, S. Pergam, L. Strawbridge, and L. Shulman. 2022. Cancer care at the beginning of the COVID-19 pandemic: Effects on patients and early interventions to mitigate stresses on care. *Cancer Journal* 28(2):107-110. https://journals.lww.com/journalppo/Abstract/2022/03000/Cancer_Care_at_the_Beginning_of_the_COVID_19.5.aspx.
- Fan, Q., D. Keene, M. Banegas, S. Gehlert, L. M. Gottlieb, K. R. Yabroff, C. E. Pollack. 2022. Housing insecurity among patients with cancer. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac136/6705075?searchresult=1>.
- Graboyes, E. M., K. H. Chaiyachati, J. S. Gall, W. Johnson, J. S. Krishnan, S. S. McManus, L. Thompson, L. N. Shulman, K. R. Yabroff. 2022. Addressing transportation insecurity among patients with cancer. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac134/6705073?searchresult=1>.
- Hyer, R. N. 2022. Insights for oncology trials garnered from the rapid development of an mRNA COVID-19 vaccine. *Cancer Journal* 28(2):146-150. https://journals.lww.com/journalppo/Fulltext/2022/03000/Insights_for_Oncology_Trials_Garnered_From_the.12.aspx.
- Karzai, F., and W. L. Dahut. 2022. Lessons from the impact of the COVID-19 pandemic at the national cancer institute: Cancer research and care. *Cancer Journal* 28(2):118-120. https://journals.lww.com/journalppo/Abstract/2022/03000/Lessons_From_the_Impact_of_the_COVID_19_Pandemic.7.aspx.
- Nekhyudov, L., L. A. Fleisher, and P. B. Jacobsen. 2022. Telemedicine across the cancer care continuum: Evidence and opportunities for clinical care, research, and policy. *Cancer Journal* 28(2):121-124. https://journals.lww.com/journalppo/Abstract/2022/03000/Telemedicine_Across_the_Cancer_Care_Continuum.8.aspx.
- Nekhyudov L., G. B. Campbell, K. H. Schmitz, G.A. Brooks, A.J. Kumar, P.A. Ganz, and D. Von Ah. 2022. Cancer-related impairments and functional limitations among long-term cancer survivors: Gaps and opportunities for clinical practice. *Cancer* 128(2): 222-229. <https://pubmed.ncbi.nlm.nih.gov/34529268/>.



2022, continued

- Oyer, R. A., L. Pierce, C. Lathan, and B. Sagar. 2022. Maintaining and advancing quality cancer care during a global pandemic. *Cancer Journal* 28(2):134-137. https://journals.lww.com/journalppo/Abstract/2022/03000/Maintaining_and_Advancing_Quality_Cancer_Care.10.aspx.
- Parikh, R. B., K. M. Basen-Engquist, C. Bradley, D. Estrin, M. Levy, J. L. Lichtenfeld, B. Malin, D. McGraw, N. J. Meropol, R. Oyer, L. Kennedy Sheldon, and L. N. Shulman. 2022. Digital health applications in oncology: An opportunity to seize. 2022. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djac108/6596055?redirectedFrom=fulltext#no-access-message>.
- Prindiville, S. A., G. A. Sarosy, D. Loose, H. Ciolino, and J. H. Doroshow. 2022. Patterns of enrollment in cancer treatment trials during the COVID-19 pandemic at national cancer institute-designated cancer centers. *Cancer Journal* 28(2):111-117. https://journals.lww.com/journalppo/Abstract/2022/03000/Patterns_of_Enrollment_in_Cancer_Treatment_Trials.6.aspx.
- Raber, M., A. Jackson, K. Basen-Engquist, C. Bradley, S. Chambers, F. N. Gany, C. Hughes-Halbert, S. T. Lindau, R. Perez-Escamilla, and H. Seligman. 2022. Food insecurity among people with cancer: Nutritional needs as an essential component of care. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac135/6705074?searchresult=1..>
- Rivera, D. R., P. G. Kluetz, K. Abdallah, S. Agrawal, D. C. Angus, R. M. Califf, E. Garrett-Mayer, R. Hyer, D. R. Lowy, and S. N. Khleif. 2022. Clinical evidence generation during a pandemic: Lessons learned for sustaining progress. *Cancer Journal* 28(2):151-156. https://journals.lww.com/journalppo/Abstract/2022/03000/Clinical_Evidence_Generation_During_a_Pandemic_.13.aspx.
- Roberts, T. J., and I. T. Lennes. 2022. Lessons for oncology from the COVID-19 pandemic: Operationalizing and scaling virtual cancer care in health systems. *Cancer Journal* 28(2):125-133. https://journals.lww.com/journalppo/Abstract/2022/03000/Lessons_for_Oncology_From_the_COVID_19_Pandemic_.9.aspx.
- Schilsky, R. L. 2022. Beyond the COVID-19 pandemic: Sustaining and improving equitable cancer care and research. *Cancer Journal* 28(2):105-106. https://journals.lww.com/journalppo/Citation/2022/03000/Beyond_the_COVID_19_Pandemic__Sustaining_and.4.aspx.
- Winkfield, K. M., and R. A. Winn. 2022. Improving equity in cancer care in the face of a public health emergency. *Cancer Journal* 28(2):128-145. https://journals.lww.com/journalppo/Abstract/2022/03000/Improving_Equity_in_Cancer_Care_in_the_Face_of_a.11.aspx

2021

- Bertagnolli, M. M. and H. Singh. 2021. Treatment of older adults with cancer - Addressing gaps in evidence. *New England Journal of Medicine* 385:1062-1065. <https://www.nejm.org/doi/full/10.1056/NEJMp2106089>.
- Houston, A. J., C. M. Gunn, M. K. Paasche-Orlow, and K. M. Basen-Engquist. 2021. Health literacy interventions in cancer: A systematic review. *Journal of Cancer Education* 36(2):240-252. <https://pubmed.ncbi.nlm.nih.gov/33155097/>.

2020

- Schilsky, R. L., S. Nass, M. M. Le Beau, and E. J. Benz, Jr. 2020. Progress in cancer research, prevention, and care. *New England Journal of Medicine* 383(10):897-990. <https://www.nejm.org/doi/full/10.1056/NEJMp2007839..>
- Shulman, L. N., L. Kennedy Sheldon, and E. J. Benz. 2020. The future of cancer care in the United States—Overcoming workforce capacity limitations. *JAMA Oncology* 6(3):327-328. <https://jamanetwork.com/journals/jamaoncology/article-abstract/2758839..>
- Panagiotou, O. A., L. Hoffman-Högg, H. Hricak, S. N. Khleif, M. A. Levy, D. Magnus, M. J. Murphy, B. Patel, R. A. Winn, S. J. Nass, C. Gatsonis, and C. R. Cogle. 2020. Clinical application of computational methods in precision oncology: A review. *JAMA Oncology* 6(8):1282-1286. <https://jamanetwork.com/journals/jamaoncology/article-abstract/2765757..>

2019

- Balogh, E. P., A. B. Bindman, S. G. Eckhardt, S. Halabi, R. D. Harvey, I. Jaiyesimi, R. Miksad, H. L. Moses, S. J. Nass, R. L. Schilsky, S. Sun, J. M. Torrente, and K. E. Warren. 2019. Challenges and opportunities to updating prescribing information for longstanding oncology drugs. *The Oncologist* 24:1-7. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066705/>.
- Takvorian, S. U., E. Balogh, S. Nass, V. L. Valentin, L. Hoffman-Högg, R. A. Oyer, R. W. Carlson, N. J. Meropol, L. Kennedy Sheldon, and L. N. Shulman. 2019. Developing and sustaining an effective and resilient oncology careforce: Opportunities for action, *Journal of the National Cancer Institute* 112(7):663-670. <https://doi.org/10.1093/jnci/djz239>.
- Kline, R. M., G. B. Rocque, E. A. Rohan, K. A. Blackley, C. A. Cantril, M. L. Pratt-Chapman, H. A. Burris, and L. N. Shulman. 2019. Patient navigation in cancer: The business case to support clinical needs. *Journal of Oncology Practice* 15(11):585-590. <https://www.ncbi.nlm.nih.gov/pubmed/31509483>.
- Lubejko, B. G., C. Cantril, L. H. Hogg, and L. Kennedy Sheldon. 2019. Novice oncology nurse navigator: Core elements in establishing training needs and building on competencies. *Clinical Journal of Oncology Nursing* 23(4):387-394. <https://www.ncbi.nlm.nih.gov/pubmed/31322621>.
- Nass, S. J., M. B. Cohen, R. Nayar, M. M. Zutter, E. P. Balogh, R. L. Schilsky, H. Hricak, and K. S. J. Elenitoba-Johnson. 2019. Improving cancer diagnosis and care: Patient access to high-quality oncologic pathology. *The Oncologist* 24(10):1287-1290. <https://www.ncbi.nlm.nih.gov/pubmed/31366725>.
- Lopez, D., M. L. Pratt-Chapman, E. A. Rohan, L. Kennedy Sheldon, K. Basen-Engquist, R. Kline, L. N. Shulman, and E. J. Flores. 2019. Establishing effective patient navigation programs in oncology. *Supportive Care in Cancer* 27(6):1985-1996. <https://www.ncbi.nlm.nih.gov/pubmed/30887125>.
- Nass, S. J., C. R. Cogle, J. A. Brink, C. P. Langlotz, E. P. Balogh, A. Muellner, D. Siegal, R. L. Schilsky, and H. Hricak. 2019. Improving cancer diagnosis and care: Patient access to oncologic imaging expertise. *Journal of Clinical Oncology* 37(20):1690-1694. <https://www.ncbi.nlm.nih.gov/pubmed/31050908>.

2018

- Kline, R. M., N. K. Arora, C. J. Bradley, E. R. Brauer, D. L. Graves, N. Buchanan Lunsford, M. S. McCabe, S. F. Nasso, L. Nekhlyudov, J. H. Rowland, R. M. Schear, and P. A. Ganz. Long-term survivorship care after cancer treatment—summary of a 2017 National Cancer Policy Forum workshop. *Journal of the National Cancer Institute* 110(12):1300-1310. <https://www.ncbi.nlm.nih.gov/pubmed/30496448>.
- Nass, S. J., M. Rothenberg, R. Pentz, H. Hricak, A. Abernethy, K. Anderson, A. W. Gee, R. D. Harvey, S. Piantadosi, M. M. Bertagnolli, D. Schrag, and R. L. Schilsky. Accelerating anticancer drug development—opportunities and trade-offs. *Nature Reviews Clinical Oncology* 15(12):777-786. <https://www.ncbi.nlm.nih.gov/pubmed/30275514..>

2018, continued

- Demark-Wahnefried, W., K. H. Schmitz, C. M. Alfano, J. R. Bail, P. J. Goodwin, C. A. Thomson, D. W. Bradley, K. S. Courneya, C. A. Befort, C. S. Denlinger, J. A. Ligibel, W. H. Dietz, M. R. Stolley, M. L. Irwin, M. M. Bamman, C. M. Apovian, B. M. Pinto, K. Y. Wolin, R. M. Ballard, A. J. Dannenberg, E. G. Eakin, M. M. Longjohn, S. D. Raffa, L. L. Adams-Campbell, J. S. Buzaglo, S. J. Nass, G. M. Massetti, E. P. Balogh, E. S. Kraft, A. K. Parekh, D. M. Sanghavi, G. S. Morris, and K. Basen-Engquist. 2018. Weight management and physical activity throughout the cancer care continuum. *CA: A Cancer Journal for Clinicians* 68(1):64-89. <https://www.ncbi.nlm.nih.gov/pubmed/29165798>.

2017

- Basen-Engquist, K., C. M. Alfano, M. Maitin-Shepard, C. A. Thomson, K. H. Schmitz, B. M. Pinto, K. Stein, D. S. Zucker, K. L. Syrjala, E. Fallon, C. Doyle, and W. Demark-Wahnefried. 2017. Agenda for translating physical activity, nutrition, and weight management interventions for cancer survivors into clinical and community practice. *Obesity* (Silver Spring) 25(Suppl 2):S9-S22. <https://www.ncbi.nlm.nih.gov/pubmed/29086526>.
- Smith, G. L., P. A. Ganz, J. E. Bekelman, S. J. Chmura, J. J. Dignam, J. A. Efstathiou, R. Jagsi, P. A. Johnstone, M. L. Steinberg, S. B. Williams, J. B. Yu, A. L. Zietman, R. R. Weichselbaum, and Y.-C. Shih. 2017. Promoting the appropriate use of advanced radiation technologies in oncology: Summary of a National Cancer Policy Forum workshop. *International Journal of Radiation Oncology • Biology • Physics* 97(3):450-461. <https://www.ncbi.nlm.nih.gov/pubmed/28011046>.

2016

- Kirch, R., G. Reaman, C. Feudtner, L. Wiener, L. A. Schwartz, L. Sung, and J. Wolfe. 2016. Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine workshop highlights and next steps. *CA: A Cancer Journal for Clinicians* 66(5):398-407. <https://www.ncbi.nlm.nih.gov/pubmed/27145249>.

2015

- Nass, S. J., L. K. Beaupin, W. Demark-Wahnefried, K. Fasciano, P. A. Ganz, B. Hayes-Lattin, M. M. Hudson, B. Nevidjon, K. C. Oeffinger, R. Rechis, L. C. Richardson, N. L. Seibel, and A. W. Smith. 2015. Identifying and addressing the needs of adolescents and young adults with cancer: Summary of an Institute of Medicine workshop. *Oncologist* 20(2):186-195. <https://www.ncbi.nlm.nih.gov/pubmed/25568146>.

2014

- Bertagnolli, M. M., R. Canetta, and S. J. Nass. 2014. Expanding public-private collaborations to enhance cancer drug development: A Report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century." *Oncologist* 19(11):1179-1185. <https://www.ncbi.nlm.nih.gov/pubmed/25326161>.
- Balogh, E. P., C. Dresler, M. E. Fleury, E. R. Gritz, T. J. Kean, M. L. Myers, S. J. Nass, B. Nevidjon, B. A. Toll, G. W. Warren, and R. S. Herbst. 2014. Reducing tobacco-related cancer incidence and mortality: Summary of an Institute of Medicine workshop. *Oncologist* 19(1):21-31. <https://www.ncbi.nlm.nih.gov/pubmed/24304712>.
- Ferrell, B. R., T. J. Smith, L. Levit, and E. Balogh. 2014. Improving the quality of cancer care: Implications for palliative care. *Journal of Palliative Medicine* 17(4):393-399. <https://www.ncbi.nlm.nih.gov/pubmed/24548217>.

2013

- Ramsey, S. D., P. A. Ganz, V. Shankaran, J. Peppercorn, and E. Emanuel. 2013. Addressing the American health-care cost crisis: Role of the oncology community. *Journal of the National Cancer Institute* 105(23):1777-1781. <https://www.ncbi.nlm.nih.gov/pubmed/24226096>.
- Balogh, E. P., P. B. Bach, P. D. Eisenberg, P. A. Ganz, R. J. Green, J. C. Gruman, S. J. Nass, L. N. Newcomer, S. D. Ramsey, J. E. Schottinger, and Y. T. Shih. 2013. Practice-changing strategies to deliver affordable, high-quality cancer care: Summary of an Institute of Medicine workshop. *Journal of Oncology Practice* 9(6s):54s-59s. <https://www.ncbi.nlm.nih.gov/pubmed/29431037>.

2012

- Demark-Wahnefried, W., E. A. Platz, J. A. Ligibel, C. K. Blair, K. S. Courneya, J. A. Meyerhardt, P. A. Ganz, C. L. Rock, K. H. Schmitz, T. Wadden, E. J. Philip, B. Wolfe, S. M. Gapstur, R. Ballard-Barbash, A. McTiernan, L. Minasian, L. Nebeling, and P. J. Goodwin. 2012. The role of obesity in cancer survival and recurrence. *Cancer Epidemiology, Biomarkers & Prevention* 21(8):1244-1259. <https://www.ncbi.nlm.nih.gov/pubmed/22695735>.
- LoRusso, P. M., R. Canetta, J. A. Wagner, E. P. Balogh, S. J. Nass, S. A. Boerner, and J. Hohnaker. 2012. Accelerating cancer therapy development: The importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. *Clinical Cancer Research* 18(22):6101-6109. <https://www.ncbi.nlm.nih.gov/pubmed/23065428>.

2011

- Nass, S. J., E. Balogh, and J. Mendelsohn. 2011. A national cancer clinical trials network: Recommendations from the Institute of Medicine. *American Journal of Therapeutics* 18(5):382-391. <https://www.ncbi.nlm.nih.gov/pubmed/21326081>.
- Balogh, E. P., P. A. Ganz, S. B. Murphy, S. J. Nass, B. R. Ferrell, and E. Stovall. 2011. Patient-centered cancer treatment planning: Improving the quality of oncology care. Summary of an Institute of Medicine workshop. *Oncologist* 16(12):1800-1805. <https://www.ncbi.nlm.nih.gov/pubmed/22128118>.

2010

- Altshuler, J. S., E. Balogh, A. D. Barker, S. L. Eck, S. H. Friend, G. S. Ginsburg, R. S. Herbst, S. J. Nass, C. M. Streeter, and J. A. Wagner. 2010. Opening up to precompetitive collaboration. *Science Translational Medicine* 2(52):52cm26. <https://www.ncbi.nlm.nih.gov/pubmed/20926831>.
- Levit, L., A. P. Smith, E. J. Benz, Jr., and B. Ferrell. 2010. Ensuring Quality Cancer Care Through the Oncology Workforce. 2010. *Journal of Oncology Practice* 6(1):7-11. <https://ascopubs.org/doi/abs/10.1200/JOP.091067>

**NATIONAL
ACADEMIES** Sciences
Engineering
Medicine

The National Academies provide independent, trustworthy advice that advances solutions to society's most complex challenges.

www.nationalacademies.org

Continue the Conversation at ASCO Quality Care Symposium

Roundtable Discussion

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care – A Decade in Review

Saturday, October 28, 2023, at 12:00-12:50 PM

- **Advancing the Continuum of Patient-Centered Cancer Care**
Ishwaria Subbiah, Sarah Cannon Research Institute
- **Workforce Considerations**
Larissa Nekhlyudov, Brigham & Women's Hospital and Dana-Farber
Cancer Institute
Narjust Florez, Dana-Farber Cancer Institute
- **Cancer Care Delivery**
Justin Bekelman, University of Pennsylvania Abramson Cancer Center
- **Evidence Generation to Inform Oncology Care**
Robin Yabroff, American Cancer Society

Optimizing Public-Private Partnerships for Clinical Cancer Research: A Workshop October 17-18, 2023

Lecture Room
National Academy of Sciences Building
2101 Constitution Ave, NW
Washington, DC 20418

Collaborators

National Cancer Policy Forum
Forum on Drug Discovery, Development, and Translation

Workshop Overview

This National Academies workshop, convened by the National Cancer Policy Forum in collaboration with the Forum on Drug Discovery, Development, and Translation, will examine opportunities to improve the care and outcomes for patients with cancer through public-private partnerships for clinical cancer research. The intent of the workshop is for participants to consider questions such as:

- What are the critical outputs of the clinical cancer research enterprise?
- Why are public-private partnerships essential to clinical cancer research?
- How can health equity be better prioritized within public-private partnerships for clinical cancer research?
- What are the characteristics of effective public-private collaborations in clinical research?
- What does each collaborator (e.g., government, industry, academia, foundation) bring to a public-private partnership?
- What are the barriers to the conduct of clinical research by public-private partnerships? What policies, strategies, and incentives are needed to overcome these challenges?
- How can precompetitive collaboration be facilitated?
- What types of studies are best suited to public-private partnerships?
- How can public-private partnerships be leveraged to promote postmarket cancer research to improve the evidence base for cancer care within health care delivery settings?

Planning Committee

Roy S. Herbst, Yale University (Co-Chair)
Richard L. Schilsky, University of Chicago (Co-Chair)
Gideon Blumenthal, Merck
Otis W. Brawley, Johns Hopkins University
Chanita Hughes-Halbert, University of Southern California
Samir N. Khleif, Georgetown University
Esther Krofah, Milken Institute and FasterCures
Scott M. Lippman, University of California, San Diego
Neal Meropol, Flatiron Health
Edith Perez, Mayo Clinic and Bolt Biotherapeutics
Kristen Rosati, Coppersmith Brockelman PLC
Lawrence Shulman, University of Pennsylvania Abramson Cancer Center
Heind Smith, Novartis Pharmaceuticals
Robert Winn, Virginia Commonwealth University Massey Cancer Center

Project Webpage

https://www.nationalacademies.org/event/40283_10-2023_optimizing-public-private-partnerships-for-clinical-cancer-research-a-workshop

Biological Effectors of Social Determinants of Health in Cancer: Identification and Mitigation: A Workshop

March 20-21, 2024

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

Workshop Statement of Task

A National Academies of Sciences, Engineering, and Medicine planning committee will plan and host a 1.5-day public workshop that will examine the biological effectors of social determinants of health (SDOH) in cancer and consider how the interaction of these two factors influences cancer risk, treatment outcomes, and health equity. The workshop will feature invited presentations and panel discussions on topics that may include:

- Examples of biological factors that could mediate the effects of SDOH, such as responses to chronic stress that affect immune function and inflammation, and their impact on cancer risk and outcomes.
- Emerging data on epigenetic changes stemming from social disadvantages and environmental stressors across the life course that may increase risk of cancer and poor outcomes.
- Opportunities to effectively measure and validate biomarkers for the impact of biological effectors of SDOH on cancer risk and outcomes.
- Linkages between biological impacts of SDOH and policy factors that influence health outcomes, such as access to health insurance coverage.
- Existing and emerging interventions to mitigate the biological effects of SDOH and the policy implications of these approaches.
- Research gaps and opportunities for interdisciplinary approaches to identify and mitigate biological effectors of SDOH in cancer.

The planning committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

Planning Committee Pending

Chanita Hughes-Halbert, University of Southern California (Co-Chair)

Stanton Gerson, Case Western Reserve University (Co-Chair)

Karen Basen-Enquist, University of Texas MD Anderson Cancer Center

Smita Bhatia, University of Alabama at Birmingham

Cathy Bradley, Colorado School of Public Health

Otis Brawley, Johns Hopkins University

Gwen Darien, National Patient Advocate Foundation

Scarlett Lin-Gomez, University of California, San Francisco

Larissa Nekhlyudov, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School

Lisa Richardson, Centers for Disease Control and Prevention

Cleo Ryals, Flatiron Health

Rob Winn, Virginia Commonwealth University Massey Cancer Center

Robin Yabroff, American Cancer Society

Clayton Yates, Johns Hopkins University

Project Webpage Pending